<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004629" GROUP_ID="HAEMATOL" ID="596403072416230845" MERGED_FROM="" MODIFIED="2009-11-11 10:47:05 +0100" MODIFIED_BY="Nicole Skoetz" REVIEW_NO="2" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2009-11-09 20:51:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Interferon-alpha for maintenance of follicular lymphoma</TITLE>
<CONTACT>
<PERSON ID="12057" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paolo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Baldo</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacist</POSITION>
<EMAIL_1>pbaldo@cro.it</EMAIL_1>
<EMAIL_2>p.baldo@tiscali.it</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pharmacy Unit, Drug Information Centre</DEPARTMENT>
<ORGANISATION>CRO Aviano - Centro di Riferimento Oncologico IRCCS</ORGANISATION>
<ADDRESS_1>Via Franco Gallini, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP>33081</ZIP>
<REGION>Friuli-Venezia-Giulia</REGION>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0434 659221</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0434 659743</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-10-03 11:35:51 +0200" MODIFIED_BY="Nicole Skoetz">
<PERSON ID="12057" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paolo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Baldo</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacist</POSITION>
<EMAIL_1>pbaldo@cro.it</EMAIL_1>
<EMAIL_2>p.baldo@tiscali.it</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pharmacy Unit, Drug Information Centre</DEPARTMENT>
<ORGANISATION>CRO Aviano - Centro di Riferimento Oncologico IRCCS</ORGANISATION>
<ADDRESS_1>Via Franco Gallini, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP>33081</ZIP>
<REGION>Friuli-Venezia-Giulia</REGION>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0434 659221</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0434 659743</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="255FB39682E26AA200DA2AF380C71326" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Maurizio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rupolo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Oncology</DEPARTMENT>
<ORGANISATION>Centro di Riferimento Oncologico - CRO Aviano (PN) Italy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A7685CA082E26AA2002589C308E7DDEC" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anna</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Compagnoni</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>compagnoni@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratorio per la Ricerca Clinica Oncologica</DEPARTMENT>
<ORGANISATION>Instituto Mario Negri</ORGANISATION>
<ADDRESS_1>Via La Masa 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11908" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Renzo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lazzarini</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacy Director</POSITION>
<EMAIL_1>rlazzarini@cro.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pharmacy Unit</DEPARTMENT>
<ORGANISATION>CRO Aviano - Centro di Riferimento Oncologico IRCCS</ORGANISATION>
<ADDRESS_1>Via Pedemontana Occidentale, 2 33081</ADDRESS_1>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0434 659514</PHONE_1>
<PHONE_2/>
<FAX_1>+39 0434 659461</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="254596C582E26AA200DA2AF32543AA26" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Alessandra</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bearz</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Oncology</DEPARTMENT>
<ORGANISATION>Centro di Riferimento Oncologico - CRO Aviano (PN) Italy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="254A06E182E26AA200DA2AF3D5A6E529" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Renato</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cannizzaro</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gastroenterology</DEPARTMENT>
<ORGANISATION>Centro di Riferimento Oncologico - CRO Aviano (PN) Italy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="25627EFA82E26AA200DA2AF3B5021BF1" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Simon</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Spazzapan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Oncology</DEPARTMENT>
<ORGANISATION>Centro di Riferimento Oncologico - CRO Aviano (PN) Italy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2565043E82E26AA200DA2AF3209950B0" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Ivana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Truccolo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Library</DEPARTMENT>
<ORGANISATION>Centro di Riferimento Oncologico - CRO Aviano (PN) Italy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aviano (PN)</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19748" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Lorenzo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moja</LAST_NAME>
<SUFFIX>MD, MSc, Dr Pub Health</SUFFIX>
<POSITION/>
<EMAIL_1>moja@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1>Via La Masa, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 39014517</PHONE_1>
<PHONE_2>+39 02 39014327</PHONE_2>
<FAX_1>+39 02 3559048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-11-09 20:51:21 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="9" MONTH="12" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="2" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="26" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-21 09:23:13 +0200" MODIFIED_BY="Nicole Skoetz"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-11 10:41:27 +0100" MODIFIED_BY="Nicole Skoetz">
<SUMMARY MODIFIED="2009-11-06 12:52:55 +0100" MODIFIED_BY="Nicole Skoetz">
<TITLE MODIFIED="2008-10-29 06:50:07 +0100" MODIFIED_BY="[Empty name]">Interferon-alpha in the maintenance therapy of follicular non-Hodgkin's lymphoma</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-06 12:52:55 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The aim of this systematic review is to outline the possible benefits (i.e. prolonging survival) and also the disadvantages (adverse events) of therapy with interferon-alpha, administered alone or in combination with other proven drug regimens (otherwise known as chemotherapy) to patients affected by follicular non-Hodgkin's lymphoma. Interferons are proteins secreted by vertebrate cells that exhibit various biological actions. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, augment natural killer cell activity, and show several other immunomodulatory functions. Interferons, types alfa-2a or alfa-2b, are usually administered in combination with other drugs to treat a variety of infective and neoplastic diseases. The results showed a significant benefit in progression-free survival in patients treated with interferon-alpha alone or combined with chemotherapy as compared with comparator therapies. There was, however, less evidence that interferon-alpha supported any benefit on overall survival. Furthermore, the presence of relevant drug-related adverse events suggested that a careful analysis of the risks and benefits has to be performed when making a specific clinical decision about this therapy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-11 10:37:30 +0100" MODIFIED_BY="Nicole Skoetz">
<ABS_BACKGROUND MODIFIED="2009-11-11 10:18:56 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Indolent non-Hodgkin's lymphoma, in particular follicular lymphoma (FL), is characterized by multiple remissions and relapses. Several studies have used interferon-alpha (IFN) to control this disease, both as induction and as maintenance therapy. It is not yet clear whether IFN can be associated with a survival benefit although it may prolong progression-free survival.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-11 10:18:56 +0100" MODIFIED_BY="Nicole Skoetz">
<P>To determine the effects of IFN in the maintenance therapy of FL. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-11-11 10:37:30 +0100" MODIFIED_BY="Nicole Skoetz">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library, Issue 4, 2008</I>), MEDLINE (1966 to 2008), DARE (1990 to 2008), SCOPUS (searched December 2008) and Current Contents (1975 to 2008). .</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-11 10:18:56 +0100" MODIFIED_BY="Nicole Skoetz">
<P> Randomised controlled trials of IFN versus no intervention or placebo, or IFN plus chemotherapy versus chemotherapy alone, in a maintenance setting in patients with non-Hodgkin's FL. Primary outcomes were overall survival and progression-free survival.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Three review authors independently assessed trial quality and extracted data. We contacted study authors for additional information. We collected adverse events information from the trials. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>We included eight trials (1563 patients). The drug was IFN alfa-2b in six trials and alfa-2a in two. Trials were heterogeneous in terms of diagnosis of FL, using several classification systems. IFN had been compared with placebo/no intervention in five trials and other chemotherapy in three. The effect of IFN was similar to that of placebo on overall survival (hazard ratio (HR) 0.90, 95% CI 0.61 to 1.34) whereas IFN was more effective when added to chemotherapy (HR 0.68, 95% confidence interval (CI) 0.52 to 0.90). Considering IFN versus all comparators, IFN was effective in prolonging progression-free survival (HR 0.66, 95% CI 0.57 to 0.77) and overall survival (fixed effects HR 0.79, 95% CI 0.67 to 0.94, I<SUP>2 </SUP>= 52%). After adjustment for heterogeneity this statistically significance disappeared (random effects HR 0.82, 95% CI 0.63 to 1.08). Toxicity and patients lost to follow up were significantly higher in the IFN groups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>There is evidence that addition of IFN as maintenance therapy for FL improves progression-free survival. A net benefit for overall survival is less evident. In the included studies, IFN was associated with significant toxicities that may have a major impact on a patient's quality of life.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-11 10:41:27 +0100" MODIFIED_BY="Nicole Skoetz">
<BACKGROUND MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Non-Hodgkin's lymphomas have increased dramatically over the last decade. Follicular lymphoma (FL) is the second<SUP> </SUP>most common lymphoma, accounting for 20% to 30% of all non-Hodgkin lymphomas (<LINK REF="REF-Armitage-1998" TYPE="REFERENCE">Armitage 1998</LINK>). The peak incidence of FL occurs in the sixth decade of life, with a slight female predominance. The median overall survival is about seven to ten years (<LINK REF="REF-Bastion-1991" TYPE="REFERENCE">Bastion 1991</LINK>). FL is a lymphoma of follicle centre B cells, usually composed of a mixture of centrocytes and centroblasts. The growth pattern may be either nodular or diffuse. Grading and the aggressiveness of FLs depend on the number of centroblastic cells per high-power field.</P>
<P>New information regarding the morphology, immunophenotype, genetics, and clinical features of neoplasms of lymphoid cells has led to the Revised European-American Classification of Lymphoid Neoplasms (REAL) (<LINK REF="REF-Harris-1994" TYPE="REFERENCE">Harris 1994</LINK>), a classification that has been adopted by the World Health Organization (WHO) (<LINK REF="REF-Harris-2000" TYPE="REFERENCE">Harris 2000</LINK>). The REAL/WHO classification includes all the lymphoid neoplasms and represents the first true international consensus on the classification of haematologic malignancies.</P>
<P>Genetically, the majority of cases show translocation (<LINK REF="REF-Capaccioli-1996" TYPE="REFERENCE">Capaccioli 1996</LINK>; <LINK REF="REF-Martinka-1997" TYPE="REFERENCE">Martinka 1997</LINK>) and Bcl-2 gene rearrangement (<LINK REF="REF-Gaulard-1992" TYPE="REFERENCE">Gaulard 1992</LINK>; <LINK REF="REF-Lopez-1999" TYPE="REFERENCE">Lopez 1999</LINK>; <LINK REF="REF-Matolcsy-1996" TYPE="REFERENCE">Matolcsy 1996</LINK>; <LINK REF="REF-Matolcsy-1997" TYPE="REFERENCE">Matolcsy 1997</LINK>).</P>
<P>Clinical presentation of FL is frequently as a widespread disease with nodal, splenic, and bone marrow involvement as well as extranodal sites. Generally it is characterized by indolent behaviour of the disease and occurrence of late relapses. After a long time it can transform into intermediate or high-grade lymphoma with an accelerated clinical course. The criteria used to define a high tumour burden are the following:</P>
<UL>
<LI>bulky disease (nodal or extranodal disease with maximum diameter &gt; 3 cm;</LI>
<LI>presence of B symptoms;</LI>
<LI>relevant splenomegaly;</LI>
<LI>important pleural or peritoneal effusion;</LI>
<LI>circulating lymphoma cells &gt; 5 x 10<SUP>9</SUP>/L, or neutrophils count &lt; 1 x 10<SUP>9</SUP>/L, or platelets &lt; 100 x 10<SUP>9</SUP>/L.</LI>
</UL>
<P>The Follicular Lymphoma International Prognostic Index (FLIPI) based on age, Ann Arbor stage, number of nodal area, haemoglobin level and serum lactate dehydrogenase appeared more appropriate to discriminate than the International Prognostic Index (<LINK REF="REF-Solal_x002d_C_x00e9_ligny-2004" TYPE="REFERENCE">Solal-Céligny 2004</LINK>). However other biological prognostic factors, as the role of the microenvironment in FL are under study (<LINK REF="REF-De-Jong-2009" TYPE="REFERENCE">De Jong 2009</LINK>).</P>
<P>Several treatment options are available today. Management may initially include a 'watch and wait' approach: the disease may remain stable and the period of watchful waiting may be as long as 72 months. Chemotherapy-based treatment is advised in the presence of high tumour burden and a negative prognostic index. CHOP (a combination of cyclophosphamide, adriamycin, vincristine, and prednisone) or CHOP-like regimens may be considered adequate therapy, as well as other polychemotherapy regimens without anthracyclines (<LINK REF="STD-Brice-1997" TYPE="STUDY">Brice 1997</LINK>; <LINK REF="REF-Dana-1993" TYPE="REFERENCE">Dana 1993</LINK>). Fludarabine may be given as an alternative second-line treatment, either as a single agent or as part of a combination regimen (<LINK REF="REF-Lenz-2004" TYPE="REFERENCE">Lenz 2004</LINK>). The availability of novel biologic agents such as rituximab presents new, greatly impacting therapeutic and maintenance opportunities for FL. Rituximab is a murine genetically engineered human monoclonal antibody that binds to the antigen CD20, which is normally located on pre-B and mature B lymphocytes, and is also expressed on more than 90% of B-cell non-Hodgkin's lymphomas. Adding rituximab to chemotherapy treatment has been positively evaluated in a recent systematic review (<LINK REF="REF-Schulz-2007" TYPE="REFERENCE">Schulz 2007</LINK>). Based on available evidence, rituximab has been recommended in recent guidelines (<LINK REF="REF-Cheung-2007" TYPE="REFERENCE">Cheung 2007</LINK>; <LINK REF="REF-NICE-TA110_x002c_-2006" TYPE="REFERENCE">NICE TA110, 2006</LINK>).</P>
<P>Other bio-modulating agents such as interferons have been used for many years as maintenance therapy for non-Hodgkin's lymphoma, but they are less frequently included in the maintenance therapy options because of significant drug-related toxicities. Interferons are cytokines, proteins secreted by vertebrate cells in response to a wide variety of inducers. They exhibit various biological actions (<LINK REF="REF-Ezaki-1996" TYPE="REFERENCE">Ezaki 1996</LINK>) that include inhibition of proliferation of normal and malignant cells, and complex immunomodulatory functions. The pharmaceutical agents actually used in therapy are derived from recombinant DNA technology and the variants (types alfa-2a, alfa-2b, alfa-2c) differ in the amino acid sequences. Up to now, there are no reliable data supporting differences in the action or the clinical efficacy of any particular type of interferon-alpha. The FDA approved only interferon alfa-2b for the treatment of FL.</P>
<P>There are no unequivocally convincing data showing that the interferon-alpha used alone or in combination with other drug regimens as maintenance therapy can prolong the overall survival time in patients with non-Hodgkin's FL (<LINK REF="REF-Brandt-2001" TYPE="REFERENCE">Brandt 2001</LINK>; <LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>). A previous meta-analysis by Allen 2001 did show a significantly increased progression-free survival rate in patients receiving interferon-alpha, both for induction and maintenance therapy (<LINK REF="REF-Allen-2001" TYPE="REFERENCE">Allen 2001</LINK>) as opposed to other studies which did not confirm a survival benefit (<LINK REF="STD-Arranz-1998" TYPE="STUDY">Arranz 1998</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>; <LINK REF="REF-Hiddemann-1998" TYPE="REFERENCE">Hiddemann 1998</LINK>; <LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>; <LINK REF="REF-Solal_x002d_C_x00e9_ligny-1998" TYPE="REFERENCE">Solal-Céligny 1998</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>To determine possible benefits or disadvantages derived from the administration of interferon-alpha in the maintenance therapy of non-Hodgkin's FL.<B>
<BR/>
</B>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-11 10:37:53 +0100" MODIFIED_BY="Nicole Skoetz">
<SELECTION_CRITERIA MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<CRIT_STUDIES MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Randomised controlled trials on patients who had a diagnosed FL were eligible for inclusion. Studies which included more than one type of lymphoma, according to international classifications (WHO, REAL, etc.), were excluded unless:</P>
<P>a) we were able to extract data specifically referring to FL patients, or</P>
<P>b) FL patients were the majority (&gt; 70%).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-28 12:57:53 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Inclusion criteria</HEADING>
<P>Patients who had a documented histologically confirmed diagnosis of non-Hodgkin's FL (WHO, REAL, etc). The criteria used to distinguish between patients with FL and other subcategories of low-grade or mantle cell lymphoma were based on classification systems widely accepted: Kiel (<LINK REF="REF-Lennert-1978" TYPE="REFERENCE">Lennert 1978</LINK>; <LINK REF="REF-Lennert-1992" TYPE="REFERENCE">Lennert 1992</LINK>; <LINK REF="REF-Stansfeld-1988" TYPE="REFERENCE">Stansfeld 1988</LINK>), Rappaport (<LINK REF="REF-Rappaport-1966" TYPE="REFERENCE">Rappaport 1966</LINK>), Working Formulation (<LINK REF="REF-NHCPLP-1982" TYPE="REFERENCE">NHCPLP 1982</LINK>), REAL (<LINK REF="REF-Harris-1994" TYPE="REFERENCE">Harris 1994</LINK>), WHO (<LINK REF="REF-Harris-2000" TYPE="REFERENCE">Harris 2000</LINK>). A summary of the various classification systems for FL is reported in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Definitions are reported in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. A schematic view of relationship between different B-cell lymphomas is presented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>Patients were included regardless of sex, age, pre or concomitant therapy, and without a pre-set time limit on the duration of interferon-alpha therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Exclusion criteria</HEADING>
<UL>
<LI>Studies enrolling patients for which the non-Hodgkin's lymphoma disease classification was not clearly follicular (according to the international classifications WHO, REAL, or WHO/REAL). This criterion was not declared in the original review protocol, but it was introduced as some studies also reported a small number of patients having lymphomas classified as low-grade or mantle cell. These studies were included because results were sufficiently clear to extract data referring specifically to FL patients.</LI>
</UL>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Interferon-alpha versus no intervention or placebo, or interferon-alpha plus chemotherapy versus the chemotherapy alone, in maintenance setting (<LINK REF="REF-Berinstein-2006" TYPE="REFERENCE">Berinstein 2006</LINK>). Possible administration of interferon-alpha included concomitance or subsequence to single or combination chemotherapy (or between two or more cycles of chemotherapy).</P>
<P>Comparisons were subgrouped for efficacy analyses with regard to interventions and controls.</P>
<P>Possible single or combination chemotherapy regimens used as control included:</P>
<UL>
<LI>CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin);</LI>
<LI>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone);</LI>
<LI>CVP (cyclophosphamide, vincristine, and prednisone);</LI>
<LI>chlorambucil;</LI>
<LI>CHVP (cyclophosphamide, doxorubicin, teniposide, and prednisone);</LI>
<LI>ProMACE (prednisone, methotrexate, doxorubicin, cyclophosphamide);</LI>
<LI>MOPP (etoposide or mechlorethamine, vincristine, procarbazine).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="6">Definition of maintenance therapy</HEADING>
<P>Maintenance therapy is defined as: "Treatment that is given to help a primary (original) treatment keep working. Maintenance therapy is often given to help keep cancer in remission" - National Cancer Institute (NCI): dictionary of cancer terms (www.cancer.gov/dictionary/ - accessed January 2009). Induction or upfront therapy with interferon-alpha was excluded.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-09-28 12:55:34 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures to be evaluated were:</P>
<UL>
<LI>overall survival;</LI>
<LI>progression-free survival.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Other outcomes considered were:</P>
<UL>
<LI>adverse events and toxicity related to drug therapy;</LI>
<LI>overall response to therapy;</LI>
<LI>adherence and coping with therapy, expressed as number of patients lost to follow up (drop outs);</LI>
<LI>quality of life during treatment, as measured using any previous validated scale;</LI>
<LI>cost-effectiveness and costs per quality-adjusted life year.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>.<BR/>We searched the following databases:</P>
<UL>
<LI>Cochrane Haematological Malignancies Group (CHMG) Trials Register;</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2008, Issue 4) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
</UL>
<UL>
<LI>MEDLINE and PREMEDLINE, through the PubMed interface (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and OVID interface (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) (January 1966 to December 2008);</LI>
<LI>The Database of Reviews of Effectiveness (DARE) (January 1990 to December 2008);</LI>
<LI>SCOPUS (no date limits, last accessed December 2008);</LI>
<LI>Current Contents: Clinical Medicine and Life Sciences (January 1975 to December 2008).</LI>
</UL>
<P>MEDLINE was searched using the search strategy (see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) together with the optimally sensitive search strategy developed by the Cochrane Collaboration for the identification of randomised controlled trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). Detailed search strategies were developed for each database (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>, <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>, <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>). Handsearching was executed to retrieve additional journal articles, eligible reports or documents from the following conference proceedings.</P>
<P>We also searched for ongoing trials in:</P>
<UL>
<LI>http://www.trialscentral.org/;</LI>
<LI>www.controlled-trials.com;</LI>
<LI>http://www.cancer.gov/search/clinical_trials/;</LI>
<LI>http://clinicaltrials.gov;</LI>
<LI>http://clinicaltrials.nci.nih.gov/;</LI>
<LI>http://doh.gov.uk/research/nrr.htm;</LI>
<LI>http://www.centerwatch.com/.</LI>
</UL>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-11 10:37:53 +0100" MODIFIED_BY="Nicole Skoetz">
<SUBSECTION>
<HEADING LEVEL="5">Study selection</HEADING>
<P>Three review authors (PB, MR and AC) looked at every report identified by the searches and made an assessment of their suitability for inclusion in the review based on the criteria set out above. Initially, the selection criteria were broad to avoid missing relevant data. The review authors then awarded each study a grade for their methodological quality. Any disagreements were resolved by discussion. The first authors of the original papers were contacted, if necessary, for any clarifications (i.e. studies published only in abstract form).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality assessment</HEADING>
<P>The criteria for quality assessment were based on the recommendations of Cochrane Reviewers' Handbook, Version 5.0.0 (<LINK REF="REF-Cochrane-Reviewers_x0027_-Handbook-2008" TYPE="REFERENCE">Cochrane Reviewers' Handbook 2008</LINK>). Evaluation of quality of reporting of trials was based on the revised CONSORT statement (Consolidated Standards of Reporting Trials) (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). The overall quality of the studies was based on the following criteria.</P>
<P>
<I>Adequacy of the randomisation process and of allocation concealment</I>
</P>
<P>A - Adequate based on one or more of the following elements: research methods and study design clearly defined; randomisation by a central office; internal coherence between protocol, presentation of results, and outcomes.</P>
<P>B - Unclear: design method was less clear; apparently adequate concealment but without other information in trial report.<BR/>C - Inadequate: not unconfounded; no evidence of internal coherence between protocol, presentation of results, and outcomes; inadequate reporting.</P>
<P>
<I>Attrition bias</I>
</P>
<P>A - Adequate: an intention-to-treat analysis was possible and drop-out rate was less than 20% for all groups.<BR/>B - Unclear: drop-out rate was more than 20%, or observed heterogeneity in drop-out rate between groups.<BR/>C - Inadequate: lack of reporting on drop-out rates and intention-to-treat analysis not possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Data extraction</HEADING>
<P>Two review authors (PB and AC) independently extracted data , analysing each trial separately and using a standardized data extraction form developed by the group. The form included all the data referred to by the authors of the original trials, the source and year of publication, the type of study, the characteristics of patients, and the characteristics of the interventions (chemotherapy regimen and dose, interferon-alpha or placebo use and dose, timing, and where necessary notes on the different levels of effectiveness of the various chemotherapy regimens), and the outcome measures as specified above. Survival data relating to FL patients were extracted directly from survival curves or from data tables.We contacted the first author of papers in order to obtain missing data . We resolved any differences or disagreements by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Data analysis</HEADING>
<P>
<I>About efficacy</I>
<BR/>The hazard ratio (HR) and associated variances (or other measures of dispersion) for overall survival and progression-free survival were extracted directly from the trial publication(s). If not reported, we obtained these data indirectly using the methods described by <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK> either from other available summary statistics or from data extracted from published Kaplan-Meier curves.</P>
<P>We obtained a pooled HR through the generic inverse variance approach from the log HR and the standard error of the log HR, using fixed-effect and random-effect models, along with assessments of heterogeneity (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). The pooled HR represents the overall risk of an event on chemotherapy regimens containing interferon-alpha versus those not containing interferon-alpha.</P>
<P>We reported ratios of treatment effects for time-to-event outcomes such that HRs less than 1.0 favour regimens containing interferon-alpha and values greater than 1.0 favour regimens that do not contain interferon-alpha. We used HR plots to show overall survival and progression-free survival .</P>
<P>We assessed the degree of heterogeneity among the trials by using the I<SUP>2-</SUP> statistic for each outcome. An I<SUP>2</SUP> value greater than 50% should be considered large (<LINK REF="REF-Cochrane-Reviewers_x0027_-Handbook-2008" TYPE="REFERENCE">Cochrane Reviewers' Handbook 2008</LINK>). If statistical evidence exists for homogeneity of effect sizes, the planned analysis will be to use a fixed-effect model. Where significant heterogeneity exists clinically or statistically, careful clinical review of the data for the source of such heterogeneity will occur. Based on this review, a decision will be made by the reviewers to either: (1) redo the analysis using the homogenous subgroup (only if a clear and compelling reason to exclude the heterogeneous data can be made); (2) abandon statistical combining of the trials in favour of a narrative review of the literature; or (3) redo the analysis using the random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
<P>Response rates were analysed as dichotomous variables (complete or partial response versus stable disease or no response) and pooled odds ratio were derived. Responses were reported on an intention-to-treat basis. We have reported ratios of treatment effects for response such that ORs less than 1.0 favour regimens containing interferon-alpha and values greater than 1.0 favour regimens that do not contain interferon-alpha.</P>
<P>
<I>About toxicity</I>
</P>
<P>We extracted toxicity data for leukocytopenia, granulocytopenia, neutropenia, neurologic symptoms, flu-like symptoms, infection, fever, other symptoms of any severity, thrombocytopenia, and grade III or grade IV events of haematological toxicity.</P>
<P>The number needed to treat (NNT) (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) has been calculated when possible.</P>
<P>All statistical analyses were performed with Review Manager Version 5.0.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-11-11 10:41:27 +0100" MODIFIED_BY="Nicole Skoetz">
<STUDY_DESCRIPTION MODIFIED="2009-11-11 10:41:27 +0100" MODIFIED_BY="Nicole Skoetz">
<P>We found 116 studies, of which 27 were eligible to be considered for inclusion (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Eight trials (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Aviles-2004" TYPE="STUDY">Aviles 2004</LINK>; <LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>; <LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>; <LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>) met the criteria to be included in the meta-analyses (see diagram in Figure 2). <LINK REF="STD-Solal_x002d_C_x00e9_ligny-1993" TYPE="STUDY">Solal-Céligny 1993</LINK> presented an interim analysis about the same patients included in <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>. Two publications, <LINK REF="STD-Cole-1998" TYPE="STUDY">Cole 1998</LINK> and <LINK REF="STD-Wirt-2001" TYPE="STUDY">Wirt 2001</LINK>, respectively refer to patients' quality of life and cost-effectiveness analyses based on data from <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>. These studies were included in this review and described qualitatively. All the included studies are described in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Reasons for exclusion of trials are described in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. One study (<LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>) performed a sequential double randomisation using interferon-alpha as initial and maintenance therapy. We considered in the analyses only patients included in the maintenance setting. In total, this review analysed 1563 patients.</P>
<P>In six of the eight included studies interferon type was alfa-2b, and in two studies was alfa-2a. Diagnosis of non-Hodgkin's lymphoma, follicular type, was performed across the studies according to: Working Formulation (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>), REAL (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>), WHO (<LINK REF="STD-Aviles-2004" TYPE="STUDY">Aviles 2004</LINK>), Rappaport (<LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>) or Kiel (<LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>) . In <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK> the diagnosis of FL was confirmed by a panel of three haemato-pathologists by mean of histologic review, but authors did not refer to any classification system. In any case, in all the included studies FL patients were in the majority (&gt; 70%). A summary of the trials included in the meta-analysis is given in additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>In general, the methods used in the studies support the conclusions. Randomisation was performed in all of the eight studies which provided data for this review. Only <LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK> reported the method of allocation concealment in details (although the method of coded envelopes used could be potentially open to abuse). All studies were well balanced: treatment and control groups had comparable baseline characteristics. Four studies provided complete information about patients who withdrew and reasons (<LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>, <LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>, <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>, <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>); one study (<LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>) provided only the percentage of withdrawals but not reasons; three reports (<LINK REF="STD-Solal_x002d_C_x00e9_ligny-1993" TYPE="STUDY">Solal-Céligny 1993</LINK>, <LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK> and <LINK REF="STD-Aviles-2004" TYPE="STUDY">Aviles 2004</LINK>) presented unclear information about withdrawals; one study clearly reported that there were no dropouts (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>). One study lost between 10% and 20% patients during the post-treatment follow up (<LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>). Intention-to-treat analysis was performed in four of eight trials (<LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>; <LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK> ).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Primary outcomes</B>
</P>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Overall survival (OS) </I>
</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interferon versus placebo or no intervention</HEADING>
<P>Five trials including 1100 patients (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Aviles-2004" TYPE="STUDY">Aviles 2004</LINK>; <LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>; <LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>) provided data for the analysis comparing interferon-alpha as maintenance therapy with placebo or no therapy. Overall, there was no difference in the risk for all-cause mortality between interferon and placebo or no intervention (HR 0.90; 95% CI 0.61 to 1.34) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). There was statistical evidence of heterogeneity (P = 0.03, I<SUP>2 </SUP>= 63%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interferon plus chemotherapy versus chemotherapy alone</HEADING>
<P>Three trials including 463 patients contributed data for the analysis comparing interferon plus chemotherapy versus chemotherapy alone (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>). When compared to chemotherapy alone, interferon plus chemotherapy resulted in a significantly decreased risk for mortality (HR 0.68 95% CI 0.52 to 0.90) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). There was no heterogeneity (P = 0.39, I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interferon versus any control</HEADING>
<P>There was not a statistically significant difference (interaction test P=0.17) between studies exploring interferon versus placebo or no intervention compared to chemotherapy (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Considering all eight trials including 1563 patients, overall interferon did improve OS when compared to any control (HR 0.79; CI 0.67 to 0.94), using fixed-effect models (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). There was marginally significant statistical heterogeneity between the trials (P=0.04, I<SUP>2 </SUP>= 52%). This effect was not maintained using the random-effects model which presents wider confidence intervals around a similar effect (HR 0.82; 95% CI 0.63 to 1.08) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Progression-free (PFS) survival</I>
</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interferon versus placebo or no intervention</HEADING>
<P>Three trials including 894 patients (<LINK REF="STD-Aviles-2004" TYPE="STUDY">Aviles 2004</LINK>; <LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>) contributed to this analysis. PFS was significantly better for interferon therapy compared to placebo or no intervention (HR 0.74;95% CI 0.61 to 0.91) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). There was no significant heterogeneity (P = 0.97, I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interferon plus chemotherapy versus chemotherapy alone</HEADING>
<P>Three trial involving 463 patients (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>; <LINK REF="REF-Solal_x002d_C_x00e9_ligny-1998" TYPE="REFERENCE">Solal-Céligny 1998</LINK>) explored the role of interferon plus chemotherapy versus chemotherapy alone. PFS was significantly better for interferon plus chemotherapy (HR 0.56; 95% CI 0.45 to 0.71). There was moderate heterogeneity among studies (P = 0.13, I<SUP>2 </SUP>= 51%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interferon versus any control</HEADING>
<P>Studies exploring interferon versus placebo or no intervention compared to chemotherapy held positive results although studies exploring interferon associated with chemotherapy resulted in an increased magnitude of effect (interaction test P=0.08). Considering all six trials including 1357 patients, overall interferon significantly improved PFS when compared to any control (HR 0.66; 95% CI 0.57 to 0.77), using fixed-effects model (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). There was no statistical heterogeneity between trials (P=0.20, I<SUP>2 </SUP>= 31%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Toxicity</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Leukocytopenia or granulocytopenia or neutropenia (Any severity)</HEADING>
<P>This analysis involved five trials (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>; <LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK> ) with 797 patients (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). There was evidence of heterogeneity across all studies (P=0.008, I<SUP>2 </SUP>= 71%). We used a random-effects model. Results studies showed a significantly higher risk of toxicity in patients treated with interferon (relative risk (RR) 5.68; 95% CI 1.28 to 25.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Infection, fever (WHO Grade 3 or 4)</HEADING>
<P>Two trials (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>) were involved in this analysis. There was no heterogeneity (P = 0.43, I<SUP>2 </SUP>= 0%) nor significant evidence of a higher risk of toxicity in patients treated with interferon-alpha (RR 2.26; 95% CI 0.34 to 15.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Neurologic symptoms</HEADING>
<P>These analyses involved two trials (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>) with 323 patients. Results demonstrated a significantly higher risk of neurologic symptoms in patients treated with interferon (RR 1.83; 95% CI 1,06 to 3.15 ) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). However, the same toxicity restricted to WHO grades 3 or 4 showed no significant evidence in patients treated with interferon (RR 1.61; 95% CI 0.41 to 6.38) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). There was no evidence of heterogeneity in either analyses (I<SUP>2</SUP>=0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Flu-like symptoms</HEADING>
<P>Any severity<BR/>This analysis involved two trials (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>). Results did not reach a significant increased risk of toxicity for patients treated with interferon (RR = 8.49; 95% CI 0.85 to 84.75) although the point estimate suggests an appreciable harm (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
<P>Severity WHO grade 3 or 4<BR/>Only <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK> reported on this outcome. There was no significant evidence of an increased risk of toxicity in patients treated with interferon (RR 2.91; 95% CI 0.12 to 70.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Thrombocytopenia</HEADING>
<P>Three trials (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK> ; <LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>) contributed to this analysis. Results showed a significantly higher risk of thrombocytopenia for patients treated with interferon-alpha (RR 5.78; 95% CI 2.17 to 15.41).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Response to therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Patients achieving complete or partial remission (overall response)</HEADING>
<P>Three trials (<LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>; <LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK> ) with 449 patients contributed data to this analysis. There was evidence of heterogeneity (P = 0.02, I<SUP>2</SUP>=75%). Results did not show a significant difference in response to treatment for patients given interferon-alpha and patients not treated (RR = 1.12; 95% CI 0.95 to 1.33) (see <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number of patients lost to follow up (drop outs)</HEADING>
<P>This analysis involved four trials (<LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>; <LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>; <LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>) with 860 patients (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>). There was significant heterogeneity between trials (P = 0.06, I<SUP>2 </SUP>= 59%). Results showed a significant greater risk to drop out in patients treated with interferon (RR=5.63; 95% CI 1.06 to 29.94).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number needed to treat (NNT) and to harm (NNH)</HEADING>
<P>All efficacy and safety results are summarised as NNT and NNH in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.<BR/>
</P>
<P>
<B>Quality of life (QoL) and cost-effectiveness evaluation</B>
</P>
<P>Two additional studies (<LINK REF="STD-Cole-1998" TYPE="STUDY">Cole 1998</LINK>; <LINK REF="STD-Wirt-2001" TYPE="STUDY">Wirt 2001</LINK>) were included in this review to assess the advantages of administering interferons in a therapeutic maintenance setting in terms of QoL. The paper by Cole (<LINK REF="STD-Cole-1998" TYPE="STUDY">Cole 1998</LINK>) was based on the patients and data from <LINK REF="REF-Solal_x002d_C_x00e9_ligny-1998" TYPE="REFERENCE">Solal-Céligny 1998</LINK>. A 'quality-adjusted time without symptoms of toxicity' (Q-TWIST) analysis, based on the method developed by Gelber et al. (<LINK REF="REF-Gelber-1995" TYPE="REFERENCE">Gelber 1995</LINK>), was applied to evaluate the clinical benefits of interferon-alpha with reference to the increased risk of toxicity or adverse events . Q-TWIST was applied to 242 patients randomised to receive a chemotherapy regimen alone (119 patients) or CHVP plus interferon alfa-2b (123 patients). The study was based on the definition of four clinical states, useful for the Q-TWIST analysis:</P>
<OL>
<LI>the time spent with toxicity derived from the chemotherapy treatment alone; or</LI>
<LI>the time spent with toxicity derived from chemotherapy plus interferon;</LI>
<LI>the time period without symptoms or without disease progression and without toxicity, and</LI>
<LI>the period following disease progression.</LI>
</OL>
<P>A quality of life-adjusted survival model was applied with the use of utility coefficients to represent the value of time in the four health states (<LINK REF="REF-Earle-2000" TYPE="REFERENCE">Earle 2000</LINK>, <LINK REF="REF-Pettengell-2008" TYPE="REFERENCE">Pettengell 2008</LINK>). CHVP chemotherapy plus interferon-alpha provided an average gain of 7.8 quality-adjusted months as compared with chemotherapy alone.</P>
<P>The paper of Wirt (<LINK REF="STD-Wirt-2001" TYPE="STUDY">Wirt 2001</LINK>) was based on the same 242 patient data from <LINK REF="REF-Solal_x002d_C_x00e9_ligny-1998" TYPE="REFERENCE">Solal-Céligny 1998</LINK> but was a cost-effectiveness analysis. The study used a Markov model based on the natural history of advanced follicular non-Hodgkin's lymphoma as altered by therapy. Results showed that interferon-alpha concomitant therapy added 9.9 quality-adjusted months at a cost of USD 13,900 (at a marginal cost-effectiveness value of USD 16,900 per quality-adjusted life-year (QALY) , that is below the conventional threshold of USD 50,000 per QALY in the USA (<LINK REF="REF-Evans-2004" TYPE="REFERENCE">Evans 2004</LINK>). Authors concluded that the addition of low-dose interferon-alpha to CHVP chemotherapy in a maintenance setting was cost effective in reference to increasing PFS time.</P>
<P>Both of these studies (<LINK REF="STD-Cole-1998" TYPE="STUDY">Cole 1998</LINK>; <LINK REF="STD-Wirt-2001" TYPE="STUDY">Wirt 2001</LINK>) are based on only one trial (<LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>), the one with most positive findings favouring interferon.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-11 10:38:13 +0100" MODIFIED_BY="Nicole Skoetz">
<SUMMARY_OF_RESULTS MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Eight eligible trials were conducted between 1993 and 2004. Interferon as a maintenance therapy for FL, after or concomitant with chemotherapy, significantly improved PFS. Impact on overall survival was less straightforward: results were fairly heterogeneous and inconsistent, the random-effects meta-analysis did not reach statistical significance providing evidence for imprecision. Although emphasis on P values and the dichotomization of results based on arbitrary thresholds ( P &lt;0.05) would be inappropriate (<LINK REF="REF-Goodman-1999" TYPE="REFERENCE">Goodman 1999</LINK>), our results suggest that the survival benefit is still uncertain given the low quality of evidence. Toxicity was in general higher with the interferon chemotherapy regimens. There was insufficient evidence to assess whether there was any benefit from interferon chemotherapy in terms of symptom control or QoL compared with chemotherapy alone because the two studies which explored QoL were based on only one trial.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-11-11 10:38:13 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The randomised trials were heterogeneous in terms of concomitant chemotherapies and interferon dosages. For instance, in the UK the most frequently used initial treatment was chlorambucil, in Europe it was CVP and in the USA it was CHOP. Trials used administration schedules of interferon-alpha with a total dose greater than 36 million of international units (MIU) monthly or less than 36 MIU monthly. The low number of included studies made it difficult to explore these differences in subgroup analyses.</P>
<P>
<BR/>Median overall survival of FL is about seven to 10 years. Against this background a novel drug should prolong life in order to be considered as first choice treatment for maintenance therapy of FL. Over the past years other novel drugs such as fludarabine-containing regimens, anti-C20 containing treatments, radioimmunotherapy and high dose chemotherapy treatments with stem-cell rescue (i.e. carmustine, carboplatin, etoposide, cyclophosphamide, cytarabine and melphalan in several combination regimens), have been introduced in clinical practice based on evidence about benefits on overall survival. Recently a novel biologic agent, rituximab, has been adopted as therapeutic and maintenance treatment for non-Hodgkin's lymphoma patients (<LINK REF="REF-Vidal-2009" TYPE="REFERENCE">Vidal 2009</LINK>). Rituximab is a well-tolerated agent and it has a great activity in relapsing patients (<LINK REF="REF-Coiffier-2007" TYPE="REFERENCE">Coiffier 2007</LINK>). In combination with chemotherapy, rituximab allowed for the longest PFS and OS described in FL (<LINK REF="REF-Coiffier-2007" TYPE="REFERENCE">Coiffier 2007</LINK>). Given the toxicity of interferon-alpha and the uncertainty about survival benefits, it is hard to hypothesize that interferon could be incorporated into these new therapeutic approaches (<LINK REF="REF-Feuerlein-2009" TYPE="REFERENCE">Feuerlein 2009</LINK>, <LINK REF="REF-Sebban-2008" TYPE="REFERENCE">Sebban 2008</LINK>). These novel agents - and particularly the monoclonal antibody rituximab - decreased the interest of investigators in understanding the real advantages of interferon in terms of OS over control chemotherapies.</P>
</APPLICABILITY_OF_FINDINGS>
<AGREEMENT MODIFIED="2009-11-11 10:18:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The use of interferon-alpha as an additive therapy for the treatment of FL has been investigated in another systematic overview (<LINK REF="REF-Brandt-2001" TYPE="REFERENCE">Brandt 2001</LINK>), and two meta-analyses (<LINK REF="REF-Allen-2001" TYPE="REFERENCE">Allen 2001</LINK>; <LINK REF="REF-Rohatiner-2005" TYPE="REFERENCE">Rohatiner 2005</LINK>). The systematic overview (<LINK REF="REF-Brandt-2001" TYPE="REFERENCE">Brandt 2001</LINK>) did not include a meta-analysis; it was based essentially on 31 randomised studies, 38 prospective studies, and 18 retrospective studies all involving patients with indolent NHL, predominantly FL. The review did not distinguish between initial (induction) interferon therapy and maintenance therapy. The results suggested that addition of interferon to initial combination chemotherapy may increase the response rate and significantly prolong remission duration but prolonged survival had not been unequivocally proven. The meta-analysis published by Allen (<LINK REF="REF-Allen-2001" TYPE="REFERENCE">Allen 2001</LINK>) selected 25 articles, of which eight studies met all the criteria for inclusion and six used interferon-alpha as maintenance therapy. Results of this review indicated that patients who received interferon-alpha ("as either induction or maintenance therapy") had significantly increased five-year survival, and approximately 20% increased progression-free survival rates at three and five years when compared with controls. Following the authors conclusions the advantages were greater in patients who received interferon-alpha with an anthracycline-containing chemotherapy regimen. The authors expressed caution about the possible literature biases and heterogeneity of the included studies. The meta-analysis published by Rohatiner et al (<LINK REF="REF-Rohatiner-2005" TYPE="REFERENCE">Rohatiner 2005</LINK>) included 10 phase III studies, evaluating a total of 1922 patients with FL. Six studies correspond with studies included in this review (ECOG study (<LINK REF="STD-Smalley-2001" TYPE="STUDY">Smalley 2001</LINK>), GELA study (<LINK REF="STD-Solal_x002d_C_x00e9_ligny-1993" TYPE="STUDY">Solal-Céligny 1993</LINK>; <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>), SWOG study (<LINK REF="STD-Fisher-2000" TYPE="STUDY">Fisher 2000</LINK>), Mexican study (<LINK REF="STD-Aviles-1996" TYPE="STUDY">Aviles 1996</LINK>), UK study (<LINK REF="STD-Rohatiner-2001" TYPE="STUDY">Rohatiner 2001</LINK>) and the EORTC study (<LINK REF="STD-Hagenbeek-1998" TYPE="STUDY">Hagenbeek 1998</LINK>)). Four studies (<LINK REF="STD-Arranz-1998" TYPE="STUDY">Arranz 1998</LINK>; <LINK REF="STD-Chisesi-1991" TYPE="STUDY">Chisesi 1991</LINK>; <LINK REF="STD-Peterson-1997" TYPE="STUDY">Peterson 1997</LINK>; <LINK REF="STD-Unterhalt--1996" TYPE="STUDY">Unterhalt 1996</LINK>) included in the Rohatiner 2005 meta-analysis were considered for inclusion in our review but were excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). The results of the Rohatiner meta-analysis showed that addition of interferon-alpha to conventional chemotherapy did not improve response rate (<LINK REF="REF-Rohatiner-2005" TYPE="REFERENCE">Rohatiner 2005</LINK>). However, authors concluded that interferon therapy may prolong remission duration and survival under specific circumstances (i.e. chemotherapy used and intensity of dose).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Interferon as a maintenance therapy for FL, after or concomitant with chemotherapy, significantly improved PFS. Impact on survival was less certain because of the low quality of evidence due to heterogeneity, inconsistency and imprecision. There is an increased incidence of adverse events related to the concomitant administration of interferon-alpha to chemotherapy. There was insufficient evidence to assess whether there was any benefit from interferon chemotherapy in terms of symptom control or QoL compared with chemotherapy alone.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The availability of novel and efficacious biologic agents makes unlikely that new resources will be invested in interferon-alpha as a maintenance agent. If any, future research should pay greater attention to the QoL and related factors for evaluating the trade-off between progression-free survival and severity and duration of adverse events.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>This review has been undertaken within the collaboration of :</P>
<UL>
<LI>the Cochrane Haematological Malignancies Group, a specialised group of researchers and consumer representatives that belong to The Cochrane Collaboration.</LI>
<LI>the Cochrane Working Group of the "Centro di Riferimento Oncologico" - CRO Aviano (Italy), which is a team working specially in the field of the best drug treatment for cancer patients and evidence-based oncology. Members: Paolo Baldo, Maurizio Rupolo, Alessandra Bearz, Renato Cannizzaro, Antonella Bertola, Simon Spazzapan, Ivana Truccolo, Luigino Dal Maso, Giuseppe Toffoli, Simona Scalone, Vincenzo Canzonieri.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-10-29 09:45:10 +0100" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>Baldo P: planning of the review, contacts, methods of the review, selection of studies, extraction of data, writing of the full review</LI>
<LI>Lazzarini R: searching for studies, evaluation of included trials at the early stage and data extraction</LI>
<LI>Cannizzaro R: concept, draft text, literature search</LI>
<LI>Bearz A: evaluation of methodological quality, evaluation of experimental design of trials</LI>
<LI>Compagnoni A: data extraction, statistical analysis, performing of all statistical tests</LI>
<LI>Moja L: general methodological quality of review, concept, statistical analysis and RevMan5 support</LI>
<LI>Rupolo M: evaluation of study quality, writing of the clinical discussion</LI>
<LI>Spazzapan S: writing of background section, evaluation of study design</LI>
<LI>Truccolo I: literature search strategy, handsearching, primary selection of studies</LI>
</UL>
<P>
<B> </B>
</P>
<P>
<B>Members of the Cochrane Working Group of the "Centro di Riferimento Oncologico" - CRO Aviano (Italy)</B>
</P>
<P>The other members of the Cochrane Working Group of the &#8220;Centro di Riferimento Oncologico&#8221;, Aviano, Italy who contributed to the review:</P>
<UL>
<LI>Canzonieri V: evaluation of the diagnostic criteria for FL in the patients of the studies extracted by the whole search strategy for the review; quality of the studies</LI>
<LI>Di Lauro V: primary selection of studies, methods of the review</LI>
<LI>Bertola A: primary selection of studies, methods of the review, English language</LI>
<LI>Scalone S: written description of studies,  methods of the review</LI>
<LI>Toffoli G: evaluation of outcomes measures and pharmacoeconomic search</LI>
<LI>Dal Maso L: contribution to the extraction of data, statistical analysis, evaluation of heterogeneity and of individual patient data</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-11 10:40:16 +0100" MODIFIED_BY="Nicole Skoetz">
<STUDIES MODIFIED="2009-11-11 10:39:13 +0100" MODIFIED_BY="Nicole Skoetz">
<INCLUDED_STUDIES MODIFIED="2009-11-11 10:20:16 +0100" MODIFIED_BY="Nicole Skoetz">
<STUDY DATA_SOURCE="PUB" ID="STD-Aviles-1996" MODIFIED="2008-10-20 10:11:56 +0200" MODIFIED_BY="[Empty name]" NAME="Aviles 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-20 10:11:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aviles A, Duque G, Talavera A, Guzmàn R</AU>
<TI>Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>1996</YR>
<VL>20</VL>
<PG>495-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aviles-2004" MODIFIED="2008-10-29 10:13:09 +0100" MODIFIED_BY="[Empty name]" NAME="Aviles 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-29 10:13:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aviles A, Neri N, Huerta-Guzman J, Pèrez F, Sotelo L</AU>
<TI>Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>11</NO>
<PG>2247</PG>
<EN>2251</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cole-1998" MODIFIED="2009-11-11 10:19:44 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Cole 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-11 10:19:44 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cole BF, Solal-Céligny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, et al</AU>
<TI>Quality-of-life adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>2339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Fisher-2000" MODIFIED="2008-10-20 15:29:47 +0200" MODIFIED_BY="[Empty name]" NAME="Fisher 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-20 15:29:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Inger JM, et al</AU>
<TI>Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>10</NO>
<PG>2010-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagenbeek-1998" MODIFIED="2008-10-29 10:15:20 +0100" MODIFIED_BY="[Empty name]" NAME="Hagenbeek 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-29 10:15:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Back R, et al</AU>
<TI>Maintenance of remission with human recombinant Interferon Alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neri-2001" MODIFIED="2008-10-30 05:10:21 +0100" MODIFIED_BY="[Empty name]" NAME="Neri 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-30 05:10:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neri N, Aviles A, Cleto S, Diaz N, Talavera A, Garcia EL et al</AU>
<TI>Chemotherapy plus interferon-alpha 2b versus chemotherapy in the treatment of follicular lymphoma</TI>
<SO>Journal of Hematotherapy and Stem Cell Research</SO>
<YR>2001</YR>
<VL>10</VL>
<PG>669-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohatiner-2001" MODIFIED="2009-03-19 17:33:25 +0100" MODIFIED_BY="[Empty name]" NAME="Rohatiner 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-19 17:33:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price CGA, Rohatiner AZS, Steward W, Deakin D, Bailey N, Norton A, et al</AU>
<TI>Interferon-alfa 2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress</TI>
<SO>Annals of Oncology</SO>
<YR>1991</YR>
<VL>2 Suppl 2</VL>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-20 15:32:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, et al</AU>
<TI>A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma</TI>
<SO>British Journal of Cancer</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>1</NO>
<PG>29-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smalley-2001" MODIFIED="2009-03-19 17:34:58 +0100" MODIFIED_BY="[Empty name]" NAME="Smalley 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-19 17:34:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM, et al</AU>
<TI>Interferon alfa combined with chemotherapy for patients with non-Hodgkin's lymphoma</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<NO>19</NO>
<PG>1336-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-20 15:33:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smalley RV, Weller E, Hawkins MJ, Oken MM, O'Connel MJ, Haase-Statz S, et al</AU>
<TI>Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alfa2a) plus an anthracycline-based induction regimen</TI>
<SO>Leukemia</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>1118-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solal_x002d_C_x00e9_ligny--1998" MODIFIED="2009-11-11 10:20:01 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Solal-Céligny  1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-11 10:20:01 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solal-Céligny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, et al</AU>
<TI>Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d' Etude des Lymphomes Folliculaires 86 Trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>7</VL>
<PG>2332-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solal_x002d_C_x00e9_ligny-1993" MODIFIED="2009-11-11 10:20:09 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Solal-Céligny 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-11-11 10:20:09 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solal-Céligny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al</AU>
<TI>Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>22</NO>
<PG>1608-14</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:44:52 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirt-2001" MODIFIED="2009-11-11 10:20:16 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Wirt 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-11 10:20:16 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wirt PD, Giles FJ, Oken MM, Solal-Cèligny, Beck R</AU>
<TI>Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>2001</YR>
<VL>40(5-6)</VL>
<PG>565-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-11-11 10:39:13 +0100" MODIFIED_BY="Nicole Skoetz">
<STUDY DATA_SOURCE="PUB" ID="STD-Arranz-1998" MODIFIED="2009-11-06 13:47:29 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Arranz 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-06 13:47:29 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arranz R, Garcia-Alfonso P, Sobrino P, Zamora P, Carrion R, Garcia-Larana J, et al</AU>
<TI>Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>4</NO>
<PG>1538-46</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:47:29 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brice-1997" MODIFIED="2009-11-11 10:20:42 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Brice 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-11-11 10:20:42 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al</AU>
<TI>Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'etude des Lymphomes Folliculaires</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>3</NO>
<PG>1110-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chisesi-1987" MODIFIED="2009-03-19 14:51:01 +0100" MODIFIED_BY="[Empty name]" NAME="Chisesi 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-03-19 14:51:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chisesi T, Capnist G, Vespignani M, Cetto G</AU>
<TI>Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma</TI>
<SO>Investigational New Drugs</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chisesi-1991" MODIFIED="2009-11-11 10:20:52 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Chisesi 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-11-11 10:20:52 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chisesi T, Congiu M, Contu A, Coser P, Moretti L, Porcellini A, et al</AU>
<TI>Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group</TI>
<SO>European Journal of Cancer</SO>
<YR>1991</YR>
<VL>27 Suppl 4</VL>
<PG>S31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-2000" MODIFIED="2009-11-11 10:20:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Davis 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-11 10:20:59 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, et al</AU>
<TI>Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin&#8217;s lymphoma with rituximab and interferon-a-2a</TI>
<SO>Clinical Cancer Research</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>7</NO>
<PG>2644-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giles-2000" MODIFIED="2009-11-11 10:39:13 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Giles 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-11 10:39:13 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, et al</AU>
<TI>A prospective randomized study of chop versus chop plus alpha-2b interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 study</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>2000</YR>
<VL>40</VL>
<NO>1-2</NO>
<PG>95-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herold-2007" MODIFIED="2009-03-27 10:29:09 +0100" MODIFIED_BY="[Empty name]" NAME="Herold 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-27 10:29:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al</AU>
<TI>Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>15</NO>
<PG>1986-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiddeman-1998" MODIFIED="2009-11-11 10:21:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Hiddeman 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-11 10:21:11 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiddeman W, Unterhalt M, Herrmann R, Woltjen HH, Kreuser ED, Trumper L, et al</AU>
<TI>Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade Lymphoma Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1922-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLaughlin-1993" MODIFIED="2008-10-20 16:04:57 +0200" MODIFIED_BY="[Empty name]" NAME="McLaughlin 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-10-20 16:04:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin P, Cabanillas F, Hagemeister FB, Swan Jr F, Romaguera JE, Taylor S, et al</AU>
<TI>CHOP-bleo plus interferon for stage IV low-grade lymphoma</TI>
<SO>Annals of Oncology</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-2004" MODIFIED="2008-10-29 10:22:33 +0100" MODIFIED_BY="[Empty name]" NAME="Morris 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-29 10:22:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, et al</AU>
<TI>Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma</TI>
<SO>Haematologica</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>12</NO>
<PG>1484-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Peterson-1993" MODIFIED="2008-10-20 16:25:51 +0200" MODIFIED_BY="[Empty name]" NAME="Peterson 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-10-20 16:25:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Peterson BA, Petroni GR, Oken MM, Johnson JL, Barcos M, MR Copper</AU>
<TI>Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: .a preliminary report of an intergroup trial (CALGB 8691 and EST 7486)</TI>
<SO>Proceeding of ASCO</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>366</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Peterson-1997" MODIFIED="2008-10-29 10:23:28 +0100" MODIFIED_BY="[Empty name]" NAME="Peterson 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-10-29 10:23:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Peterson BA, Petroni GR, Oken MM, Johnson JL, Barcos M, MR Copper</AU>
<TI>Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas.an intergroup phase III trial (CALGB 8691 and EST 7486)</TI>
<SO>Proceedings of ASCO, Abstract 48</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>14a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salles-2008" MODIFIED="2009-03-27 10:23:33 +0100" MODIFIED_BY="[Empty name]" NAME="Salles 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-03-27 10:23:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salles G, Mounier N, de Guibert S, Morshhauser F, Doyen C, Rossi JF et al</AU>
<TI>Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>112</VL>
<NO>13</NO>
<PG>4824-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sebban-2006" MODIFIED="2009-03-27 11:12:28 +0100" MODIFIED_BY="[Empty name]" NAME="Sebban 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-27 11:12:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al</AU>
<TI>Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>8</NO>
<PG>2540-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unterhalt--1996" MODIFIED="2008-10-29 10:24:53 +0100" MODIFIED_BY="[Empty name]" NAME="Unterhalt  1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-29 10:24:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;vedere anche riferimenti a Atti ?????????????? Study ID 21-Unterhalt b1996&lt;/p&gt;" NOTES_MODIFIED="2008-10-29 10:24:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trumper L, et al</AU>
<TI>Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma</TI>
<SO>Leukemia</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>836-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zinzani-1997" MODIFIED="2009-11-06 13:51:27 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Zinzani 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-11-06 13:51:27 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zinzani PL, Bendandi M, Magagnoli M, Rondelli D, De Vivo A, Benni M, et al</AU>
<TI>Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma
</TI>
<SO>European Journal of Haematology</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>2</NO>
<PG>82-8</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:51:27 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-11-11 10:40:16 +0100" MODIFIED_BY="Nicole Skoetz">
<ADDITIONAL_REFERENCES MODIFIED="2009-11-11 10:40:16 +0100" MODIFIED_BY="Nicole Skoetz">
<REFERENCE ID="REF-Allen-2001" MODIFIED="2009-11-11 10:21:27 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Allen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Allen IE, Ross SD, Borden SP, Monroe MW, Kupelnick B, Connelly JE, et al</AU>
<TI>Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma</TI>
<SO>Journal of Immunotherapy</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>58-65</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:51:43 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1999" MODIFIED="2008-11-11 12:01:06 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Andersen PK</AU>
<TI>Calculating the number needed to treat for trials where the outcome is time to an event</TI>
<SO>British Medical Journal</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>1492-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-1998" MODIFIED="2008-10-29 10:25:53 +0100" MODIFIED_BY="[Empty name]" NAME="Armitage 1998" TYPE="JOURNAL_ARTICLE">
<AU>Armitage JO, Weisemburger DD</AU>
<TI>New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>8</NO>
<PG>2780-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bastion-1991" MODIFIED="2009-11-11 10:39:34 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bastion 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B</AU>
<TI>Assessment of prognostic factors in 127 patients followed for 10 years</TI>
<SO>Annals of Oncology</SO>
<YR>1991</YR>
<VL>22 Suppl 2</VL>
<PG>123-9</PG>
<IDENTIFIERS MODIFIED="2009-11-11 10:39:34 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Bentz-2004" MODIFIED="2009-11-11 10:21:40 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bentz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bentz JS, Rowe LR, Anderson SR, Gupta PK, McGrath CM</AU>
<TI>Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material</TI>
<SO>Cancer Cytopathology</SO>
<YR>2004</YR>
<VL>102</VL>
<NO>2</NO>
<PG>124-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berinstein-2006" MODIFIED="2008-10-29 10:27:29 +0100" MODIFIED_BY="[Empty name]" NAME="Berinstein 2006" TYPE="JOURNAL_ARTICLE">
<AU>Berinstein NL</AU>
<TI>Principles of maintenance therapy</TI>
<SO>Leukemia Research</SO>
<YR>2006</YR>
<VL>30 Suppl 1</VL>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2001" MODIFIED="2009-11-11 10:23:13 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Brandt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brandt L, Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care</AU>
<TI>A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma</TI>
<SO>Acta Oncologica</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>2-3</NO>
<PG>213-23</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:52:39 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Capaccioli-1996" MODIFIED="2009-11-06 13:52:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Capaccioli 1996" TYPE="JOURNAL_ARTICLE">
<AU>Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni E, Bevilacqua A, et al</AU>
<TI>A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines</TI>
<SO>Oncogene</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>10</NO>
<PG>3937-44</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:52:59 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-2007" MODIFIED="2009-11-11 10:21:56 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Cheung 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care</AU>
<TI>Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>161-76</PG>
<IDENTIFIERS MODIFIED="2009-11-06 13:53:34 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Reviewers_x0027_-Handbook-2008" MODIFIED="2009-11-06 14:04:22 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Cochrane Reviewers' Handbook 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</SO>
<YR>2008, available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coiffier-2007" MODIFIED="2009-03-11 20:06:28 +0100" MODIFIED_BY="[Empty name]" NAME="Coiffier 2007" TYPE="JOURNAL_ARTICLE">
<AU>Coiffier B</AU>
<TI>Rituximab therapy in malignant lymphoma</TI>
<SO>Oncogene</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>3603-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dana-1993" MODIFIED="2009-11-06 14:04:38 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dana 1993" TYPE="JOURNAL_ARTICLE">
<AU>Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al</AU>
<TI>Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>4</NO>
<PG>644-51</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:04:38 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-De-Jong-2009" MODIFIED="2009-11-11 10:22:05 +0100" MODIFIED_BY="Nicole Skoetz" NAME="De Jong 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, et al</AU>
<TI>Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols</TI>
<SO>Haematologica</SO>
<YR>2009</YR>
<VL>94</VL>
<NO>1</NO>
<PG>70-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2009-11-08 16:29:04 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ.</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis.</TI>
<SO>Egger M, Davey Smith G, Altman DG (editors). Systematic Reviews in Health Care: Meta-analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<PB>BMJ Publication Group, 487p., ISBN 072791488X</PB>
<CY>London (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-03-30 15:36:28 +0200" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeVita-2005" MODIFIED="2009-11-06 14:07:06 +0100" MODIFIED_BY="Nicole Skoetz" NAME="DeVita 2005" TYPE="BOOK">
<AU>DeVita VT, Heilman S, Rosemberg SA</AU>
<SO>Principles and Practice of Oncology</SO>
<YR>2005</YR>
<EN>7th Edition</EN>
<ED>Lippincot Williams &amp; Wilkins (LWW)</ED>
<PB>Lippincot Williams &amp; Wilkins (LWW)</PB>
<IDENTIFIERS MODIFIED="2009-11-06 14:07:06 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2009-11-11 10:22:12 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Systematic Reviews: Identifying relevant studies for systematic reviews</TI>
<SO>British Medical Journal</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>1</NO>
<PG>1286-91</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:07:12 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Dogan-2005" MODIFIED="2008-10-28 09:27:24 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dogan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dogan A</AU>
<TI>Modern histological classification of low grade B-cell lymphomas</TI>
<SO>Best Practice &amp; Research Clinical Haematology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>1</NO>
<PG>11-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Earle-2000" MODIFIED="2008-10-29 10:31:19 +0100" MODIFIED_BY="[Empty name]" NAME="Earle 2000" TYPE="JOURNAL_ARTICLE">
<AU>Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, et al</AU>
<TI>Systematic overview of cost-utility assessments in oncology</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>18</NO>
<PG>3302-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-2004" MODIFIED="2009-11-11 10:22:22 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Evans 2004" TYPE="JOURNAL_ARTICLE">
<AU>Evans C, Tavakoli M, Crawford B</AU>
<TI>Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal</TI>
<SO>Health Care Management Science</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>1</NO>
<PG>43-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ezaki-1996" MODIFIED="2009-11-11 10:23:41 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Ezaki 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ezaki K</AU>
<TI>Cytokine therapy for hematological malignancies</TI>
<SO>International Journal of Hematology</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>1</NO>
<PG>17-29</PG>
<IDENTIFIERS MODIFIED="2009-11-11 10:23:41 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Feuerlein-2009" MODIFIED="2009-11-11 10:22:35 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Feuerlein 2009" TYPE="JOURNAL_ARTICLE">
<AU>Feuerlein K, Zucca E, Ghielmini M</AU>
<TI>First-line treatment of follicular lymphoma &#8211; a patient-oriented algorithm</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>3</NO>
<PG>325-34</PG>
<IDENTIFIERS MODIFIED="2009-11-11 10:22:30 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Gaulard-1992" MODIFIED="2009-11-11 10:23:47 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Gaulard 1992" TYPE="JOURNAL_ARTICLE">
<AU>Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, et al</AU>
<TI>Expression of the bcl-2 gene product in follicular lymphoma</TI>
<SO>The American Journal of Pathology</SO>
<YR>1992</YR>
<VL>140</VL>
<NO>5</NO>
<PG>1089-95</PG>
<IDENTIFIERS MODIFIED="2009-11-11 10:23:47 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Gelber-1995" MODIFIED="2009-11-11 10:23:55 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Gelber 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gelber RD, Cole BF, Gelber S</AU>
<TI>Comparing treatments using quality-adjusted survival. The Q-TWiST method</TI>
<SO>The American Statistician</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1999" MODIFIED="2009-11-11 10:24:05 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Goodman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Goodman SN</AU>
<TI>Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>130</VL>
<PG>995-1004</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hankin-1999" MODIFIED="2009-11-11 10:39:53 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Hankin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hankin RC, Hunter SV</AU>
<TI>Mantle cell lymphoma: molecular and immunophenotypic diagnostic aids</TI>
<SO>Archives of Pathology &amp; Laboratory Medicine</SO>
<YR>1999</YR>
<VL>123</VL>
<PG>1182-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-1994" MODIFIED="2009-11-06 14:10:14 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Harris 1994" TYPE="JOURNAL_ARTICLE">
<AU>Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al</AU>
<TI>A revised European-American classification of lymphoid neoplasms. a proposal from the International Lymphoma Study Group</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>5</NO>
<PG>1361-92</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:10:14 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2000" MODIFIED="2009-11-06 14:10:21 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Harris 2000" TYPE="JOURNAL_ARTICLE">
<AU>Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al</AU>
<TI>The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Comittee meeting - Airlie House, Virginia, November 1997</TI>
<SO>The Hematology Journal</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>1</NO>
<PG>53-66</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:10:21 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Hiddemann-1998" MODIFIED="2009-11-06 14:10:40 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Hiddemann 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hiddemann W, Griesinger F, Unterhalt M</AU>
<TI>Interferon alfa for the treatment of follicular lymphomas</TI>
<SO>The Cancer Journal from Scientific American</SO>
<YR>1998</YR>
<VL>4 Suppl 2</VL>
<PG>13-8</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:10:40 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Lennert-1978" MODIFIED="2009-11-11 10:24:19 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lennert 1978" TYPE="BOOK">
<AU>Lennert K, Mohri N, Stein H, Kaiserling E, Muller-Hermelink HK</AU>
<SO>Malignant lymphomas: other than Hodgkin's disease: histology, cytology, ultrastructure, immunology</SO>
<YR>1978</YR>
<PB>Berlin: Springer-Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lennert-1992" MODIFIED="2009-11-11 10:24:26 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lennert 1992" TYPE="BOOK">
<AU>Lennert K, Feller AC</AU>
<SO>Histopathology of non-Hodgkin's lymphomas (based on the updated Kiel Classification) with a section on clinical therapy by M. Engelhard and G. Brittinger</SO>
<YR>1992</YR>
<PB>Berlin, Germany, Springer-Verlag</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lenz-2004" MODIFIED="2009-11-11 10:24:34 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lenz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lenz G, Hiddeman W, Dreyling M</AU>
<TI>The role of fludarabine in the treatment of follicular and mantle cell lymphoma</TI>
<SO>Cancer</SO>
<YR>2004</YR>
<VL>101</VL>
<NO>5</NO>
<PG>883-93</PG>
<IDENTIFIERS MODIFIED="2009-01-23 13:03:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lopez-1999" MODIFIED="2009-11-06 14:11:54 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lopez 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lopez GA, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, et al</AU>
<TI>Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>9</NO>
<PG>3081-7</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:11:54 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Mann-1982" MODIFIED="2009-11-06 14:11:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Mann 1982" TYPE="JOURNAL_ARTICLE">
<AU>Mann R, Berard C</AU>
<TI>Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method</TI>
<SO>Hematological Oncology</SO>
<YR>1982</YR>
<VL>1</VL>
<PG>187-92</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:11:59 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Martinka-1997" MODIFIED="2009-11-06 14:12:09 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Martinka 1997" TYPE="JOURNAL_ARTICLE">
<AU>Martinka M, Comeau T, Foyle A, Anderson D, Greer W</AU>
<TI>Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma</TI>
<SO>Clinical and Investigative Medecine Clinique et Experimentale</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>6</NO>
<PG>364-70</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:12:09 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Matolcsy-1996" MODIFIED="2009-11-06 14:12:16 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Matolcsy 1996" TYPE="JOURNAL_ARTICLE">
<AU>Matolcsy A, Casali P, Warnke RA, Knowles DM</AU>
<TI>Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>10</NO>
<PG>3937-44</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:12:16 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Matolcsy-1997" MODIFIED="2009-11-06 14:12:26 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Matolcsy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Matolcsy A, Warnke RA, Knowles DM</AU>
<TI>Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma</TI>
<SO>Annals of Oncology</SO>
<YR>1997</YR>
<VL>8 Suppl 2</VL>
<PG>119-22</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:12:26 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-11-11 10:24:49 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D, for the CONSORT Group</AU>
<TI>The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>The Journal of American Medicine Association</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHCPLP-1982" MODIFIED="2008-10-29 10:40:05 +0100" MODIFIED_BY="[Empty name]" NAME="NHCPLP 1982" TYPE="OTHER">
<AU>The Non-Hodgkin's Lymphoma Pathologic Classification Project</AU>
<TI>NHLPCP. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage</TI>
<SO>Cancer</SO>
<YR>1982</YR>
<VL>49</VL>
<PG>2112-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-TA110_x002c_-2006" MODIFIED="2008-10-28 09:27:24 +0100" MODIFIED_BY="Nicole Skoetz" NAME="NICE TA110, 2006" TYPE="OTHER">
<AU>National Institute for Health and Clinica Excellence (NICE) Project Team</AU>
<TI>Rituximab for the treatment of follicular lymphoma</TI>
<SO>NICE Technology Appraisal Guidance 110 - www.nice.org.uk/TA110</SO>
<YR>2006</YR>
<VL>T.A.G. 110</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ott-2002" MODIFIED="2009-11-11 10:25:02 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Ott 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M, et al</AU>
<TI>Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>10</NO>
<PG>3806-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2009-11-11 10:40:16 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pettengell-2008" MODIFIED="2009-11-06 14:13:25 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pettengell 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, et al</AU>
<TI>The impact of follicular lymphoma on health-related quality of life</TI>
<SO>Annals of Oncology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>3</NO>
<PG>570-6</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:13:25 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Rappaport-1966" MODIFIED="2009-11-11 10:25:09 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Rappaport 1966" TYPE="BOOK_SECTION">
<AU>Rappaport H</AU>
<TI>Tumors of the hematopoietic system</TI>
<SO>Atlas of Tumor Pathology</SO>
<YR>1966</YR>
<VL>Fasc. 8</VL>
<NO>Sect. 3</NO>
<PG>241-3</PG>
<PB>Armed Force Institute of Pathology</PB>
<CY>Bethesda</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rohatiner-2005" MODIFIED="2008-10-29 10:42:00 +0100" MODIFIED_BY="[Empty name]" NAME="Rohatiner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al</AU>
<TI>Meta-analysis to evaluate the role of interferon in follicular lymphoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>10</NO>
<PG>2215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenwald-2003" MODIFIED="2009-11-06 14:14:22 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Rosenwald 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al</AU>
<TI>The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma</TI>
<SO>Cancer Cell</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>2</NO>
<PG>100-2</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:14:22 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2007" MODIFIED="2009-11-06 14:14:44 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Schulz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al</AU>
<TI>Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<NO>9</NO>
<PG>706-14</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:14:44 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Sebban-2008" MODIFIED="2009-11-11 10:25:29 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Sebban 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al</AU>
<TI>Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>21</NO>
<PG>3614-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solal_x002d_C_x00e9_ligny-1998" MODIFIED="2009-11-11 10:25:38 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Solal-Céligny 1998" TYPE="JOURNAL_ARTICLE">
<AU>Solal-Céligny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, et al</AU>
<TI>Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas; final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>7</NO>
<PG>2332-8</PG>
<IDENTIFIERS MODIFIED="2009-11-06 14:15:56 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Solal_x002d_C_x00e9_ligny-2004" MODIFIED="2009-10-23 19:49:42 +0200" MODIFIED_BY="[Empty name]" NAME="Solal-Céligny 2004" TYPE="JOURNAL_ARTICLE">
<AU>Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al</AU>
<TI>Follicular Lymphoma International Prognostic Index (FLIPI)</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>5</NO>
<PG>1258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stansfeld-1988" MODIFIED="2008-10-29 10:44:50 +0100" MODIFIED_BY="[Empty name]" NAME="Stansfeld 1988" TYPE="JOURNAL_ARTICLE">
<AU>Stansfeld AG, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, et al</AU>
<TI>Updated Kiel classification for lymphomas</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>i</VL>
<PG>292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vidal-2009" MODIFIED="2009-10-07 15:00:50 +0200" MODIFIED_BY="[Empty name]" NAME="Vidal 2009" TYPE="COCHRANE_REVIEW">
<AU>Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O</AU>
<TI>Rituximab as maintenance therapy for patients with follicular lymphoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-10-07 14:58:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-11-11 10:38:30 +0100" MODIFIED_BY="Nicole Skoetz">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-11 10:38:30 +0100" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-11-08 15:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aviles-1996">
<CHAR_METHODS MODIFIED="2009-09-28 13:21:21 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised controlled trial; method of randomisation: coded envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-29 09:47:10 +0100" MODIFIED_BY="[Empty name]">
<P>98 patients affected by low-grade malignant lymphoma in complete remission after a conventional chemotherapy regimen and radiotherapy, if necessary. Most patients had follicular mixed or follicular small cell histology.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Induction therapy consisted of two cycles of two low doses of methotrexate with leucovorin, followed by two cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone and bleomycin), given every three weeks and followed by six cycles of CVP (cyclophosphamide, vincristine and prednisone), given monthly. Patients in complete response (98) were randomised to receive: interferon alfa-2b, 5.0 MIU, three times a week for one year, as maintenance therapy, or no further treatment (control group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-15 12:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>Overall survival, progression-free survival, quality of life, treatment-related toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:22:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aviles-2004">
<CHAR_METHODS MODIFIED="2009-09-28 13:21:02 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised controlled trial; method of randomisation not declared.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-29 09:48:20 +0100" MODIFIED_BY="[Empty name]">
<P>384 patients affected by follicular lymphoma (according to REAL/World Health Organization Classification), in complete response after 6 cycles of chemotherapy (CEOP-Bleo) and adjuvant radiotherapy if necessary.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:22:08 +0100" MODIFIED_BY="[Empty name]">
<P>Initally, the patients received the same chemotherapy regimen (CEOP-Bleo, cyclophosphamide, epirubicin, vincristine, prednisone and bleomycin at standard doses) and adjuvant radiotherapy if necessary. Patients in complete response were randomised to receive: interferon alfa-2b, 5.0 MIU three times a week or no treatment (control group). Complete response was defined as disappearance of all detectable evidence of the progression.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-29 09:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>The primary end-points were overall survival (OS), event-free survival (EFS). Toxicity was reported only in relation to total number of cycles, and not referred to individual patient treatment-related toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data about treatment-related toxicity (table II of the original paper) were not usable for the purpose of the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Cole-1998">
<CHAR_METHODS MODIFIED="2009-11-06 13:50:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>A quality of life-adjusted survival analysis based on the data of GELF 86 multi-centre trial (Groupe D'Etude Des Lymphomes Folliculaires) (see <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Analysis based on 242 patients who had advanced follicular lymphoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients randomised to receive a chemotherapy regimen (CHVP, cyclophosphamide, doxorubicin, teniposide and prednisone) alone or CHVP plus interferon alfa-2b, 5 MIU three times weekly for 18 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-29 09:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>To estimate health-state durations and to evaluate the trade off of toxicity versus improved clinical outcome achieved with concomitant administration of interferon therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Fisher-2000">
<CHAR_METHODS MODIFIED="2009-09-28 12:54:44 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-10-03 12:12:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;Table 3: what about the 571 patients?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-11-11 10:18:58 +0100" NOTES_MODIFIED_BY="Nicole Skoetz">
<P>268 eligible patients; 86% had follicular lymphoma, and only 14% had working formulation (WF) type A.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:22:52 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients, randomised to receive interferon alfa-2b consolidation (maintenance) therapy (2 MIU three times a week for two years) or observation alone. Induction therapy consisted of six to eight cycles of chemotherapy (ProMACE, prednisone, methotrexate, doxorubicin, cyclophosphamide at day 1, and MOPP, etoposide/mechlorethamine, vincristine, procarbazine, and prednisone at day 8) or chemotherapy plus radiotherapy. Responding patients were randomised to observation alone or to interferon alfa-2b maintenance therapy, given at 2 MIU/m<SUP>2</SUP> three times weekly for 2 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-21 09:37:18 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Overall survival (OS) and progression-free survival (PFS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-11 10:38:30 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Hagenbeek-1998">
<CHAR_METHODS MODIFIED="2009-09-28 12:54:29 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-07 15:11:43 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-10-03 12:13:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;Please mention the 347 patients, too (Table 3)&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-10-07 15:11:43 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>242 patients with stages III and IV low-grade malignant NHL (predominantly follicular)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-11 10:38:30 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Two arms of patients randomised to receive: interferon alfa-2a, 3.0 MIU, three times a week or no further therapy (control group)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-15 12:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>Overall survival (OS), time to progression (TTP), treatment-related toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:22:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neri-2001">
<CHAR_METHODS MODIFIED="2009-09-28 12:53:52 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-29 09:54:29 +0100" MODIFIED_BY="[Empty name]">
<P>55 patients with follicular NHL lymphoma, stages I or II (according to REAL classification).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:22:59 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients randomised to receive: chemotherapy COPP (cyclophosphamide, vincristine, prednisone and procarbazine) plus interferon alfa-2b (5.0 MIU three times a week) or chemotherapy COPP alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, event-free survival (EFS), treatment-related toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:23:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rohatiner-2001">
<CHAR_METHODS MODIFIED="2009-09-28 13:20:35 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised controlled clinical trial (sequential).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-23 19:25:10 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-10-03 12:13:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;Table 3: 108 were evaluated, please de&lt;/span&gt;&lt;span modified=&quot;2009-10-03 12:14:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;scribe briefly, why 108 only&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-10-23 19:25:10 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>231 patients affected by stage III or IV follicular lymphoma. We considered in the analyses only patients included in the second randomization group (maintenance setting, N = 108). </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients randomised to receive either chlorambucil 10 mg daily in a specific schedule) or the same therapy given concurrently with interferon alfa-2b (3 MIU three times a week) for 18 weeks. Responding patients were then randomised to receive maintenance interferon therapy at the same dose for six months or no further therapy (control group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Evaluation of the clinical course of patients with follicular lymphoma, complete and partial remission, survival time, time of remission, treatment-related toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:23:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smalley-2001">
<CHAR_METHODS MODIFIED="2008-10-29 09:56:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-23 19:26:24 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-10-03 12:14:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;Table 3: 291 patients&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-10-23 19:26:24 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>249 eligible patients who had low-grade or intermediate-grade NHL. Only patients with FL were included in the analysis for this systematic review (N= 166).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients, randomised to receive a chemotherapy regimen including cyclophosphamide, vincristine, doxorubicin and prednisone given with or without (control group) the concomitant administration of interferon alfa-2a (6 MIU/m<SUP>2</SUP> on days 22-26, for 8-10 cycles).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-29 09:56:46 +0100" MODIFIED_BY="[Empty name]">
<P>Overall survival, time to treatment failure (TTF).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:23:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998">
<CHAR_METHODS MODIFIED="2009-11-06 13:50:16 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Final analysis derived from <LINK REF="STD-Solal_x002d_C_x00e9_ligny-1993" TYPE="STUDY">Solal-Céligny 1993</LINK>.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-07 15:10:53 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-10-03 12:14:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;273 patients&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-10-07 15:10:53 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>242 patients who had small-cell or mixed-cell follicular lymphoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:23:13 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients, randomised to receive a chemotherapy regimen including cyclophosphamide, teniposide, doxorubicin and prednisone (CHVP) given with or without (control group) the concomitant administration of interferon alfa-2b (5 MIU/m<SUP>2</SUP> three times weekly for 18 months).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, progression-free survival (PFS), response to treatment and toxicity related to drug therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:23:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny-1993">
<CHAR_METHODS MODIFIED="2009-09-28 13:21:44 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel randomised controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-07 15:11:04 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-10-03 12:14:00 +0200&quot; modified_by=&quot;Nicole Skoetz&quot; class=&quot;inserted&quot;&gt;273 patients&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-10-07 15:11:04 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>242 patients who had small-cell or mixed-cell follicular lymphoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:23:20 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms of patients, randomised to receive a chemotherapy regimen including cyclophosphamide, teniposide, doxorubicin and prednisone (CHVP) given with or without (control group) the concomitant administration of interferon alfa-2b (5 MIU/m<SUP>2</SUP> three times weekly for 18 months).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival, progression-free survival (PFS), response to treatment and toxicity related to drug therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-06 13:50:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The 1993 paper contains some data on patient compliance, and toxicity (not extractable from <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-08 15:23:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wirt-2001">
<CHAR_METHODS MODIFIED="2009-11-06 13:50:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>A cost-effectiveness analysis based on the data of GELF 86 multi-centre trial (Groupe D'Etude Des Lymphomes Folliculaires) (see <LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-28 12:52:36 +0200" MODIFIED_BY="[Empty name]">
<P>Analysis based on 242 patients who had advanced follicular lymphoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-08 15:23:28 +0100" MODIFIED_BY="[Empty name]">
<P>Two arms, patients randomised to receive chemotherapy (CHVP, cyclophosphamide, doxorubicin, teniposide and prednisone) alone or CHVP plus interferon alfa-2b, 5 MIU three times weekly for 18 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-06 12:51:57 +0100" MODIFIED_BY="Nicole Skoetz">
<P>To estimate the cost-effectiveness of interferon therapy added to a regimen of chemotherapy in the treatment of advanced follicular lymphoma.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-10-29 10:00:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arranz-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-29 10:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>The study also admitted patients with lymphoma in marginal areas (mucosa-associated lymphoid tissue (MALT) and monocytoids) and patients with mantle-cell lymphoma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-19 17:31:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brice-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-19 14:58:14 +0100" MODIFIED_BY="[Empty name]">
<P>The study included a treatment arm in which interferon alfa-2b was used as induction therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-19 14:58:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chisesi-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-19 14:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>This pilot study (not randomised) enrolled patients with clinically incurable diffuse poorly differentiated lymphocytic NHL (DPDL) and patients with diffuse mixed NHL (DM).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Chisesi-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Interferon was used in all patients as induction therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Davis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Interferon was used in all patients as induction therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giles-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study admitted patients with different classifications of lymphoma, not only or prevalently in the follicular form.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Herold-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The study compared two treatment regimens not including interferon (mitoxantrone, chlorambucil, prednisolone (MCP) with rituximab or MCP alone). All patients achieving a complete or partial remission were treated with interferon alfa-2a until relapse, but no data about efficacy of interferon therapy were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-28 12:50:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiddeman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-28 12:50:28 +0200" MODIFIED_BY="[Empty name]">
<P>The study compared patients with follicle-centre lymphoma or with (FCLs) and mantle-cell lymphomas (MCLs).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-McLaughlin-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The study evaluated the integration of interferon alfa-n1 into a conventional chemotherapy regimen (CHOP-bleo) was not a randomised control trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-19 15:01:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morris-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-19 15:01:52 +0100" MODIFIED_BY="[Empty name]">
<P>The study was not a randomised clinical trial; furthermore, the study enrolled patients who had prior treatment (with one to three different chemotherapy regimens) and patients who had no prior treatment. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Peterson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Data from this study, the preliminary data of the same study reported in American Society of Clinical Oncology (ASCO) proceedings 1997 (<LINK REF="STD-Peterson-1997" TYPE="STUDY">Peterson 1997</LINK>), were only reported as an abstract presented at ASCO in 1993, and published in the proceedings of ASCO Vol 12 (n. *1240 pag 366); the paper evaluated the efficacy of interferon alfa-2b administered as induction therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-19 15:02:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peterson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-19 15:02:55 +0100" MODIFIED_BY="[Empty name]">
<P>Data from this study were only reported as an abstract presented at American Society of Clinical Oncology (ASCO) in 1997, and published in the proceedings of ASCO Vol 16 (n. *48 pag 14a); and evaluated the efficacy of interferon alfa-2b administered as induction therapy. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Salles-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Interferon was used in all patients as induction therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Sebban-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 10:18:58 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Interferon was used in all patients as induction therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-28 12:50:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Unterhalt--1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-28 12:50:19 +0200" MODIFIED_BY="[Empty name]">
<P>The study compared patients with centroblastic-centrocytic (Kiel classification) or with follicle centre lymphoma (REAL classification) or with mantle cell lymphoma. In the study tables CB-CC (centroblastic-centrocitic lymphoma) were presented in the same group as FCL (follicle centre) patients, and the former were 81% against 19% of the FCL.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-29 10:06:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zinzani-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-29 10:06:33 +0100" MODIFIED_BY="[Empty name]">
<P>The study enrolled patients affected by B-cell chronic lymphocytic leukemia (B-CLL).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-11 10:38:26 +0100" MODIFIED_BY="Nicole Skoetz">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-11 10:38:26 +0100" MODIFIED_BY="Nicole Skoetz" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-11 10:38:26 +0100" MODIFIED_BY="Nicole Skoetz" RESULT="YES" STUDY_ID="STD-Aviles-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Aviles-2004">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-20 10:58:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cole-1998">
<DESCRIPTION>
<P>B - unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fisher-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hagenbeek-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Neri-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rohatiner-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smalley-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wirt-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-11-11 10:18:59 +0100" MODIFIED_BY="Nicole Skoetz">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-29 10:10:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-19 14:43:00 +0200" MODIFIED_BY="[Empty name]">Additional table 1. Definitions for follicular lymphomas in the different classification systems.</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TD>
<P>
<B>ICD-O code</B>
</P>
</TD>
<TD>
<P>
<B>Kiel (1992)</B>
</P>
</TD>
<TD>
<P>
<B>REAL (1994)</B>
</P>
</TD>
<TD>
<P>
<B>WHO (2001)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<U>B-cell lymphomas</U>
</P>
</TD>
<TD>
<P>
<U>B-cell neoplasms</U>
</P>
</TD>
<TD>
<P>
<U>B-cell neoplasms</U>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="6">
<P>
<B>9690/3</B>
</P>
</TD>
<TD ROWSPAN="5">
<P>Centroblastic-centrocytic lymphoma,</P>
<P>follicular, follicular and diffuse</P>
<P>- with an increased number of centroblasts</P>
<P>Centroblastic lymphoma, follicular</P>
</TD>
<TD>
<P>Follicle centre lymphoma, follicular</P>
</TD>
<TD>
<P>Follicular lymphoma</P>
</TD>
</TR>
<TR>
<TD>
<P>Grade I</P>
</TD>
<TD>
<P>Grade 1</P>
</TD>
</TR>
<TR>
<TD>
<P>Grade II</P>
</TD>
<TD>
<P>Grade 2</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Grade III</P>
</TD>
<TD>
<P>Grade 3a</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grade 3b</P>
</TD>
</TR>
<TR>
<TD>
<P>Centroblastic-centrocytic lymphoma, diffuse</P>
</TD>
<TD>
<P>Follicle centre lymphoma, diffuse, small cell</P>
</TD>
<TD>
<P>Diffuse follicle centre lymphoma</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>9673/3</B>
</P>
</TD>
<TD>
<P>Centrocytic (mantle cell) lymphoma</P>
<P>Centroblastic lymphoma, centrocytoid</P>
</TD>
<TD>
<P>Mantle cell lymphoma</P>
</TD>
<TD>
<P>Mantle cell lymphoma</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Comparison of definitions for follicular lymphomas in the different classification systems. Note that in the Kiel classification, tumours with a follicular growth pattern or a follicular component were not regarded as a separate entity. ICD-O code = International Classification of Disease for Oncology codes; WHO = World Health Organization.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-11-11 10:18:59 +0100" MODIFIED_BY="Nicole Skoetz" NO="2">
<TITLE MODIFIED="2009-10-23 19:59:47 +0200" MODIFIED_BY="[Empty name]">Additional table 2. Summary of NNT/NNH by outcome.</TITLE>
<TABLE COLS="3" ROWS="13">
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Analysis ref. number</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcome</P>
</TH>
<TH>
<P>NNT/NNH</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.1</P>
</TD>
<TD>
<P>Overall survival (random-effects model)</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.2</P>
</TD>
<TD>
<P>Overall survival (fixed-effects model), best scenario / worst scenario</P>
</TD>
<TD>
<P>34 / 14</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.3</P>
</TD>
<TD>
<P>Progression-free survival (fixed-effects model), best scenario / worst scenario</P>
</TD>
<TD>
<P>16 / 7</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.6</P>
</TD>
<TD>
<P>Toxicity (any severity): leukocytopenia/granulocytopenia/neutropenia</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.7</P>
</TD>
<TD>
<P>Toxicity (any severity): neurologic symptoms</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.8</P>
</TD>
<TD>
<P>Toxicity any severity: flu-like symptoms</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.9</P>
</TD>
<TD>
<P>Toxicity any severity: thrombocytopenia</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.13</P>
</TD>
<TD>
<P>Toxicity WHO grade III - IV: haematological toxicity</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.14</P>
</TD>
<TD>
<P>Toxicity WHO grade III - IV: flu-like symptoms</P>
</TD>
<TD>
<P>136</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.15</P>
</TD>
<TD>
<P>Toxicity WHO grade III - IV: neurologic symptoms</P>
</TD>
<TD>
<P>87</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.16</P>
</TD>
<TD>
<P>Toxicity WHO grade III - IV: infection/fever</P>
</TD>
<TD>
<P>84</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1.17</P>
</TD>
<TD>
<P>Tolerability - Number of patients withdrawing from treatment for any reason</P>
</TD>
<TD>
<P>16</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Number needed to treat (NNT) by outcome. For overall survival (OS), using fixed-effects model, best scenario: 5-years survival = 0.85 (<LINK REF="STD-Aviles-2004" TYPE="STUDY">Aviles 2004</LINK>); estimated pooled HR = 0.79; 95%CI 0.67 to 0.94, NNT= 34; 95% CI 21 to 120; worst scenario: 5-years survival = 0.56 (<LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>), estimated pooled HR = 0.79; 95%CI 0.67 to 0.94, NNT = 14; 95% CI 9 to 51. For progression-free survival, fixed-effects model, best scenario: 5-years survival = 0.80 (<LINK REF="STD-Neri-2001" TYPE="STUDY">Neri 2001</LINK>); estimated pooled HR = 0.66; 95% CI 0.57 to 0.77, NNT = 16; 95% CI 12 to 24; worst scenario: 5-years survival = 0.20 (<LINK REF="STD-Solal_x002d_C_x00e9_ligny--1998" TYPE="STUDY">Solal-Céligny 1998</LINK>); estimated pooled HR = 0.66; 95% CI 0.57, 0.77, NNT = 7; 95% CI 5 to 11. Numbers were calculated following the methodology showed by Altman et al (<LINK REF="REF-Altman-1999" TYPE="REFERENCE">Altman 1999</LINK>). For adverse events/toxicity numbers needed to harm (NNH) were calculated.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-10-23 20:07:29 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-10-29 10:08:08 +0100" MODIFIED_BY="[Empty name]">Additional table 3. Summary of studies included in meta-analysis.</TITLE>
<TABLE COLS="5" ROWS="9">
<TR>
<TD>
<P>
<B>Study name</B>
</P>
</TD>
<TD>
<P>
<B>Publication status</B>
</P>
</TD>
<TD>
<P>
<B>Patients: total enrolled/measured</B>
</P>
</TD>
<TD>
<P>
<B>Treatment arm</B>
</P>
</TD>
<TD>
<P>
<B>Control arm</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Aviles 1996</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>98/98</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P>Aviles 2004</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>384/384</P>
</TD>
<TD>
<P>191</P>
</TD>
<TD>
<P>193</P>
</TD>
</TR>
<TR>
<TD>
<P>Fisher 2000</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>571/268</P>
</TD>
<TD>
<P>144</P>
</TD>
<TD>
<P>124</P>
</TD>
</TR>
<TR>
<TD>
<P>Hagenbeek 1998</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>347/242</P>
</TD>
<TD>
<P>122</P>
</TD>
<TD>
<P>120</P>
</TD>
</TR>
<TR>
<TD>
<P>Neri 2001</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>55/55</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>Rohatiner 2001</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>126/108 (patients from second randomisation only)</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>48</P>
</TD>
</TR>
<TR>
<TD>
<P>Smalley 2001</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>291/166</P>
</TD>
<TD>
<P>78</P>
</TD>
<TD>
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>Solal-Cèligny 1998</P>
</TD>
<TD>
<P>full paper</P>
</TD>
<TD>
<P>273/242</P>
</TD>
<TD>
<P>123</P>
</TD>
<TD>
<P>119</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-11-11 10:27:34 +0100" MODIFIED_BY="Nicole Skoetz">
<COMPARISON ID="CMP-001" MODIFIED="2009-11-11 10:27:34 +0100" MODIFIED_BY="Nicole Skoetz" NO="1">
<NAME>Interferon maintenance therapy versus other therapy</NAME>
<IV_OUTCOME CHI2="14.59849184828688" CI_END="1.0784360332930119" CI_START="0.6290757530766528" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="0.823661313762398" ESTIMABLE="YES" I2="52.04984136206204" I2_Q="46.03847456340864" ID="CMP-001.01" LOG_CI_END="0.03279439031780197" LOG_CI_START="-0.20129705381984006" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08425133175101907" MODIFIED="2009-11-11 10:26:04 +0100" MODIFIED_BY="Nicole Skoetz" NO="1" P_CHI2="0.04150476448479934" P_Q="0.17341508200916766" P_Z="0.15829988728972588" Q="1.8531722220771378" RANDOM="YES" SCALE="7.54" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.071566655448361" TOTALS="YES" TOTAL_1="794" TOTAL_2="769" WEIGHT="100.0" Z="1.4108125693345692">
<NAME>Overall survival (HR, random-effects model)</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.866309510260512" CI_END="1.3436981384379032" CI_START="0.6080045454786488" DF="4" EFFECT_SIZE="0.9038664591196224" ESTIMABLE="YES" I2="63.18897417542726" ID="CMP-001.01.01" LOG_CI_END="0.1283017154923205" LOG_CI_START="-0.2160931739033907" LOG_EFFECT_SIZE="-0.043895729205535056" MODIFIED="2009-02-02 16:02:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.028108393916029373" P_Z="0.61733956199904" STUDIES="5" TAU2="0.12122719442155128" TOTAL_1="565" TOTAL_2="535" WEIGHT="62.906536587702696" Z="0.4996244193340408">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<IV_DATA CI_END="1.0531047191194867" CI_START="0.1598143137810008" EFFECT_SIZE="0.410245302259044" ESTIMABLE="YES" ESTIMATE="-0.891" LOG_CI_END="0.022471558910548278" LOG_CI_START="-0.796384325662143" LOG_EFFECT_SIZE="-0.3869563833757974" ORDER="20" SE="0.481" STUDY_ID="STD-Aviles-1996" TOTAL_1="48" TOTAL_2="50" WEIGHT="6.241764260449082"/>
<IV_DATA CI_END="0.8928232671269145" CI_START="0.4340335806283201" EFFECT_SIZE="0.6225072525676868" ESTIMABLE="YES" ESTIMATE="-0.474" LOG_CI_END="-0.04923450047060785" LOG_CI_START="-0.3624766683736748" LOG_EFFECT_SIZE="-0.20585558442214133" ORDER="21" SE="0.184" STUDY_ID="STD-Aviles-2004" TOTAL_1="191" TOTAL_2="193" WEIGHT="17.935452348811136"/>
<IV_DATA CI_END="1.536385335561037" CI_START="0.6771703094631235" EFFECT_SIZE="1.019997320161417" ESTIMABLE="YES" ESTIMATE="0.0198" LOG_CI_END="0.18650015327358926" LOG_CI_START="-0.1693020917902205" LOG_EFFECT_SIZE="0.00859903074168435" ORDER="22" SE="0.209" STUDY_ID="STD-Fisher-2000" TOTAL_1="144" TOTAL_2="124" WEIGHT="16.40643365735475"/>
<IV_DATA CI_END="2.234707179938812" CI_START="0.7694262253451863" EFFECT_SIZE="1.3112750703845881" ESTIMABLE="YES" ESTIMATE="0.271" LOG_CI_END="0.3492206243502221" LOG_CI_START="-0.11383301515865958" LOG_EFFECT_SIZE="0.1176938045957813" ORDER="24" SE="0.272" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" WEIGHT="12.990687039193991"/>
<IV_DATA CI_END="3.048064998010121" CI_START="0.7374868935354006" EFFECT_SIZE="1.4993025000567668" ESTIMABLE="YES" ESTIMATE="0.405" LOG_CI_END="0.48402422381459476" LOG_CI_START="-0.13224569347296083" LOG_EFFECT_SIZE="0.17588926517081696" ORDER="23" SE="0.362" STUDY_ID="STD-Rohatiner-2001" TOTAL_1="60" TOTAL_2="48" WEIGHT="9.332199281893734"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.8790101159492303" CI_END="0.8990279927078663" CI_START="0.5170940842032141" DF="2" EFFECT_SIZE="0.6818225990404894" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.0462267855868017" LOG_CI_START="-0.2864304307303408" LOG_EFFECT_SIZE="-0.16632860815857128" MODIFIED="2009-02-02 16:02:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3908212843922777" P_Z="0.006640646742890174" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="234" WEIGHT="37.09346341229731" Z="2.714347497888029">
<NAME>Studies evaluating Interferon therapy plus CT vs CT alone</NAME>
<IV_DATA CI_END="4.073963122348575" CI_START="0.30770422500916517" EFFECT_SIZE="1.119631932948586" ESTIMABLE="YES" ESTIMATE="0.113" LOG_CI_END="0.6100170934336576" LOG_CI_START="-0.5118665405235228" LOG_EFFECT_SIZE="0.04907527645506745" ORDER="16" SE="0.659" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="3.7378902381257237"/>
<IV_DATA CI_END="1.1943384535691948" CI_START="0.5243518047887031" EFFECT_SIZE="0.7913618158955839" ESTIMABLE="YES" ESTIMATE="-0.234" LOG_CI_END="0.07712741530975885" LOG_CI_START="-0.28037723284048066" LOG_EFFECT_SIZE="-0.10162490876536093" ORDER="18" SE="0.21" STUDY_ID="STD-Smalley-2001" TOTAL_1="78" TOTAL_2="88" WEIGHT="16.347001700272696"/>
<IV_DATA CI_END="0.8420068182600886" CI_START="0.3859556421141489" EFFECT_SIZE="0.5700677873780134" ESTIMABLE="YES" ESTIMATE="-0.562" LOG_CI_END="-0.07468439172987122" LOG_CI_START="-0.4134626059293839" LOG_EFFECT_SIZE="-0.2440734988296276" ORDER="19" SE="0.199" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="123" TOTAL_2="119" WEIGHT="17.00857147389889"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="14.598491848286876" CI_END="0.9417002900733127" CI_START="0.6660648602201233" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="0.7919807270867965" ESTIMABLE="YES" I2="52.049841362062025" I2_Q="46.03847456340854" ID="CMP-001.02" LOG_CI_END="-0.026087295803912378" LOG_CI_START="-0.1764834779405791" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10128538687224568" MODIFIED="2009-11-11 10:26:17 +0100" MODIFIED_BY="Nicole Skoetz" NO="2" P_CHI2="0.04150476448479956" P_Q="0.17341508200916822" P_Z="0.008292961551230112" Q="1.8531722220771343" RANDOM="NO" SCALE="7.76" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="794" TOTAL_2="769" WEIGHT="100.0" Z="2.6399035881032424">
<NAME>Overall survival (HR, fixed-effects model)</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.866309510260512" CI_END="1.0891718991233381" CI_START="0.6985754708819125" DF="4" EFFECT_SIZE="0.8722779214799793" ESTIMABLE="YES" I2="63.18897417542726" ID="CMP-001.02.01" LOG_CI_END="0.03709642791847487" LOG_CI_START="-0.15578666783615674" LOG_EFFECT_SIZE="-0.05934511995884092" MODIFIED="2009-02-02 16:02:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.028108393916029373" P_Z="0.22779436047767465" STUDIES="5" TAU2="0.0" TOTAL_1="565" TOTAL_2="535" WEIGHT="60.79743928791573" Z="1.2060600471230711">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<IV_DATA CI_END="1.0531047191194867" CI_START="0.1598143137810008" EFFECT_SIZE="0.410245302259044" ESTIMABLE="YES" ESTIMATE="-0.891" LOG_CI_END="0.022471558910548278" LOG_CI_START="-0.796384325662143" LOG_EFFECT_SIZE="-0.3869563833757974" ORDER="5" SE="0.481" STUDY_ID="STD-Aviles-1996" TOTAL_1="48" TOTAL_2="50" WEIGHT="3.3733288036627593"/>
<IV_DATA CI_END="0.8928232671269145" CI_START="0.4340335806283201" EFFECT_SIZE="0.6225072525676868" ESTIMABLE="YES" ESTIMATE="-0.474" LOG_CI_END="-0.04923450047060785" LOG_CI_START="-0.3624766683736748" LOG_EFFECT_SIZE="-0.20585558442214133" ORDER="6" SE="0.184" STUDY_ID="STD-Aviles-2004" TOTAL_1="191" TOTAL_2="193" WEIGHT="23.052242596414803"/>
<IV_DATA CI_END="1.536385335561037" CI_START="0.6771703094631235" EFFECT_SIZE="1.019997320161417" ESTIMABLE="YES" ESTIMATE="0.0198" LOG_CI_END="0.18650015327358926" LOG_CI_START="-0.1693020917902205" LOG_EFFECT_SIZE="0.00859903074168435" ORDER="7" SE="0.209" STUDY_ID="STD-Fisher-2000" TOTAL_1="144" TOTAL_2="124" WEIGHT="17.86718997605869"/>
<IV_DATA CI_END="2.234707179938812" CI_START="0.7694262253451863" EFFECT_SIZE="1.3112750703845881" ESTIMABLE="YES" ESTIMATE="0.271" LOG_CI_END="0.3492206243502221" LOG_CI_START="-0.11383301515865958" LOG_EFFECT_SIZE="0.1176938045957813" ORDER="9" SE="0.272" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" WEIGHT="10.548993368082552"/>
<IV_DATA CI_END="3.048064998010121" CI_START="0.7374868935354006" EFFECT_SIZE="1.4993025000567668" ESTIMABLE="YES" ESTIMATE="0.405" LOG_CI_END="0.48402422381459476" LOG_CI_START="-0.13224569347296083" LOG_EFFECT_SIZE="0.17588926517081696" MODIFIED="2008-11-05 14:25:52 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.362" STUDY_ID="STD-Rohatiner-2001" TOTAL_1="60" TOTAL_2="48" WEIGHT="5.955684543696924"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.87901011594923" CI_END="0.8990279927078662" CI_START="0.5170940842032141" DF="2" EFFECT_SIZE="0.6818225990404894" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.046226785586801745" LOG_CI_START="-0.2864304307303408" LOG_EFFECT_SIZE="-0.16632860815857128" MODIFIED="2009-02-02 16:02:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3908212843922777" P_Z="0.006640646742890167" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="234" WEIGHT="39.202560712084264" Z="2.7143474978880295">
<NAME>Studies evaluating Interferon therapy plus CT vs CT alone</NAME>
<IV_DATA CI_END="4.073963122348575" CI_START="0.30770422500916517" EFFECT_SIZE="1.119631932948586" ESTIMABLE="YES" ESTIMATE="0.113" LOG_CI_END="0.6100170934336576" LOG_CI_START="-0.5118665405235228" LOG_EFFECT_SIZE="0.04907527645506745" ORDER="1" SE="0.659" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="1.7971238100313383"/>
<IV_DATA CI_END="1.1943384535691948" CI_START="0.5243518047887031" EFFECT_SIZE="0.7913618158955839" ESTIMABLE="YES" ESTIMATE="-0.234" LOG_CI_END="0.07712741530975885" LOG_CI_START="-0.28037723284048066" LOG_EFFECT_SIZE="-0.10162490876536093" ORDER="3" SE="0.21" STUDY_ID="STD-Smalley-2001" TOTAL_1="78" TOTAL_2="88" WEIGHT="17.69743141370113"/>
<IV_DATA CI_END="0.8420068182600886" CI_START="0.3859556421141489" EFFECT_SIZE="0.5700677873780134" ESTIMABLE="YES" ESTIMATE="-0.562" LOG_CI_END="-0.07468439172987122" LOG_CI_START="-0.4134626059293839" LOG_EFFECT_SIZE="-0.2440734988296276" ORDER="4" SE="0.199" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="123" TOTAL_2="119" WEIGHT="19.708005488351798"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.242753715293653" CI_END="0.7693338056148632" CI_START="0.567219266268791" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.6605913689540905" ESTIMABLE="YES" I2="30.965483619274522" I2_Q="67.442304050013" ID="CMP-001.03" LOG_CI_END="-0.11388518362955695" LOG_CI_START="-0.2462490262521412" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.18006710494084913" MODIFIED="2009-11-11 10:26:32 +0100" MODIFIED_BY="Nicole Skoetz" NO="3" P_CHI2="0.20320347038566866" P_Q="0.07967762170781811" P_Z="9.678961408224091E-8" Q="3.071470418349427" RANDOM="NO" SCALE="7.98" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="686" TOTAL_2="671" WEIGHT="100.00000000000001" Z="5.332650269012993">
<NAME>Progression-free survival (HR, fixed-effects model)</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours interferon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.07083746619730052" CI_END="0.9068113309729695" CI_START="0.607354284770772" DF="2" EFFECT_SIZE="0.7421291985531357" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.04248306182707038" LOG_CI_START="-0.2165579002988353" LOG_EFFECT_SIZE="-0.12952048106295289" MODIFIED="2009-02-02 16:03:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9652011704020984" P_Z="0.0035384136071819703" STUDIES="3" TAU2="0.0" TOTAL_1="457" TOTAL_2="437" WEIGHT="57.818488145534616" Z="2.9166246009168675">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<IV_DATA CI_END="1.0143763086622724" CI_START="0.5250436119799194" EFFECT_SIZE="0.7297888742690568" ESTIMABLE="YES" ESTIMATE="-0.315" LOG_CI_END="0.006199097460571484" LOG_CI_START="-0.2798046210596202" LOG_EFFECT_SIZE="-0.13680276179952433" ORDER="13" SE="0.168" STUDY_ID="STD-Aviles-2004" TOTAL_1="191" TOTAL_2="193" WEIGHT="21.418811743985525"/>
<IV_DATA CI_END="1.1893325372253343" CI_START="0.5120196597778954" EFFECT_SIZE="0.7803599432780343" ESTIMABLE="YES" ESTIMATE="-0.248" LOG_CI_END="0.07530330027918755" LOG_CI_START="-0.29071336330320047" LOG_EFFECT_SIZE="-0.10770503151200646" ORDER="14" SE="0.215" STUDY_ID="STD-Fisher-2000" TOTAL_1="144" TOTAL_2="124" WEIGHT="13.077870041368255"/>
<IV_DATA CI_END="1.0045645876475173" CI_START="0.5344301705365678" EFFECT_SIZE="0.7327138758693325" ESTIMABLE="YES" ESTIMATE="-0.311" LOG_CI_END="0.001977864585680521" LOG_CI_START="-0.27210903232950306" LOG_EFFECT_SIZE="-0.13506558387191134" ORDER="15" SE="0.161" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" WEIGHT="23.321806360180837"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.100445830746926" CI_END="0.7121135608673277" CI_START="0.44539703805234365" DF="2" EFFECT_SIZE="0.5631813835410533" ESTIMABLE="YES" I2="51.22481596993356" ID="CMP-001.03.02" LOG_CI_END="-0.1474507438274859" LOG_CI_START="-0.35125267540660576" LOG_EFFECT_SIZE="-0.24935170961704592" MODIFIED="2009-02-02 16:03:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12870648312667254" P_Z="1.6183882319358615E-6" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="234" WEIGHT="42.1815118544654" Z="4.796032761280962">
<NAME>Studies evaluating Interferon therapy plus CT vs CT alone</NAME>
<IV_DATA CI_END="0.6464202383542712" CI_START="0.04044976128130064" EFFECT_SIZE="0.1617020232675885" ESTIMABLE="YES" ESTIMATE="-1.822" LOG_CI_END="-0.18948505497482168" LOG_CI_START="-1.3930840370806281" LOG_EFFECT_SIZE="-0.7912845460277248" ORDER="10" SE="0.707" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="1.2094143284516876"/>
<IV_DATA CI_END="0.9033131342983701" CI_START="0.4693934332089478" EFFECT_SIZE="0.6511599291810325" ESTIMABLE="YES" ESTIMATE="-0.429" LOG_CI_END="-0.044161675019614086" LOG_CI_START="-0.328462990453376" LOG_EFFECT_SIZE="-0.18631233273649506" ORDER="11" SE="0.167" STUDY_ID="STD-Smalley-2001" TOTAL_1="78" TOTAL_2="88" WEIGHT="21.676092461624563"/>
<IV_DATA CI_END="0.7319183062471849" CI_START="0.3657103599023065" EFFECT_SIZE="0.5173684443380216" ESTIMABLE="YES" ESTIMATE="-0.659" LOG_CI_END="-0.13553739042521346" LOG_CI_START="-0.4368627367232724" LOG_EFFECT_SIZE="-0.28620006357424294" ORDER="12" SE="0.177" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="123" TOTAL_2="119" WEIGHT="19.296005064389146"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="12.814083094744719" CI_END="0.9073723982717334" CI_START="0.6192059205799479" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.749566782335426" ESTIMABLE="YES" I2="53.17651715197083" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.042214435848708605" LOG_CI_START="-0.20816489976878735" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.125189667808748" MODIFIED="2009-11-11 10:26:43 +0100" MODIFIED_BY="Nicole Skoetz" NO="4" P_CHI2="0.04608526279679459" P_Q="0.3530970090608333" P_Z="0.0031053304080053976" Q="0.8622961741370823" RANDOM="NO" SCALE="6.85" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="650" TOTAL_2="645" WEIGHT="100.0" Z="2.957114241751654">
<NAME>Sensitivity analysis: Overall survival (excluding Fisher 2000, fixed-effects model)</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.072776804658407" CI_END="1.0645014594410223" CI_START="0.6274917062599877" DF="3" EFFECT_SIZE="0.8172917698722373" ESTIMABLE="YES" I2="70.21675295522705" ID="CMP-001.04.01" LOG_CI_END="0.027146261196368742" LOG_CI_START="-0.20239201000521176" LOG_EFFECT_SIZE="-0.08762287440442154" MODIFIED="2009-02-02 16:03:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.017957572467224958" P_Z="0.13455593160568152" STUDIES="4" TAU2="0.0" TOTAL_1="421" TOTAL_2="411" WEIGHT="52.269305408329615" Z="1.4963751112660664">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<IV_DATA CI_END="1.0531047191194867" CI_START="0.1598143137810008" EFFECT_SIZE="0.410245302259044" ESTIMABLE="YES" ESTIMATE="-0.891" LOG_CI_END="0.022471558910548278" LOG_CI_START="-0.796384325662143" LOG_EFFECT_SIZE="-0.3869563833757974" ORDER="29" SE="0.481" STUDY_ID="STD-Aviles-1996" TOTAL_1="48" TOTAL_2="50" WEIGHT="4.107163510757091"/>
<IV_DATA CI_END="0.8928232671269145" CI_START="0.4340335806283201" EFFECT_SIZE="0.6225072525676868" ESTIMABLE="YES" ESTIMATE="-0.474" LOG_CI_END="-0.04923450047060785" LOG_CI_START="-0.3624766683736748" LOG_EFFECT_SIZE="-0.20585558442214133" ORDER="30" SE="0.184" STUDY_ID="STD-Aviles-2004" TOTAL_1="191" TOTAL_2="193" WEIGHT="28.067032638594966"/>
<IV_DATA CI_END="2.234707179938812" CI_START="0.7694262253451863" EFFECT_SIZE="1.3112750703845881" ESTIMABLE="YES" ESTIMATE="0.271" LOG_CI_END="0.3492206243502221" LOG_CI_START="-0.11383301515865958" LOG_EFFECT_SIZE="0.1176938045957813" ORDER="32" SE="0.272" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" WEIGHT="12.843823759357036"/>
<IV_DATA CI_END="3.048064998010121" CI_START="0.7374868935354006" EFFECT_SIZE="1.4993025000567668" ESTIMABLE="YES" ESTIMATE="0.405" LOG_CI_END="0.48402422381459476" LOG_CI_START="-0.13224569347296083" LOG_EFFECT_SIZE="0.17588926517081696" ORDER="31" SE="0.362" STUDY_ID="STD-Rohatiner-2001" TOTAL_1="60" TOTAL_2="48" WEIGHT="7.2512854996205185"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.8790101159492303" CI_END="0.8990279927078663" CI_START="0.5170940842032141" DF="2" EFFECT_SIZE="0.6818225990404894" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.0462267855868017" LOG_CI_START="-0.2864304307303408" LOG_EFFECT_SIZE="-0.16632860815857128" MODIFIED="2009-02-02 16:03:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3908212843922777" P_Z="0.006640646742890174" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="234" WEIGHT="47.730694591670385" Z="2.714347497888029">
<NAME>Studies evaluating Interferon therapy plus CT vs CT alone</NAME>
<IV_DATA CI_END="4.073963122348575" CI_START="0.30770422500916517" EFFECT_SIZE="1.119631932948586" ESTIMABLE="YES" ESTIMATE="0.113" LOG_CI_END="0.6100170934336576" LOG_CI_START="-0.5118665405235228" LOG_EFFECT_SIZE="0.04907527645506745" ORDER="25" SE="0.659" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="2.1880705280964885"/>
<IV_DATA CI_END="1.1943384535691948" CI_START="0.5243518047887031" EFFECT_SIZE="0.7913618158955839" ESTIMABLE="YES" ESTIMATE="-0.234" LOG_CI_END="0.07712741530975885" LOG_CI_START="-0.28037723284048066" LOG_EFFECT_SIZE="-0.10162490876536093" ORDER="27" SE="0.21" STUDY_ID="STD-Smalley-2001" TOTAL_1="78" TOTAL_2="88" WEIGHT="21.5473346261286"/>
<IV_DATA CI_END="0.8420068182600886" CI_START="0.3859556421141489" EFFECT_SIZE="0.5700677873780134" ESTIMABLE="YES" ESTIMATE="-0.562" LOG_CI_END="-0.07468439172987122" LOG_CI_START="-0.4134626059293839" LOG_EFFECT_SIZE="-0.2440734988296276" ORDER="28" SE="0.199" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="123" TOTAL_2="119" WEIGHT="23.995289437445294"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.551804540292785" CI_END="0.758633298942511" CI_START="0.5470908049260321" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.6442369922335642" ESTIMABLE="YES" I2="38.94811764605467" I2_Q="59.2013785179216" ID="CMP-001.05" LOG_CI_END="-0.11996809858340181" LOG_CI_START="-0.26194058444286245" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1909543415131321" MODIFIED="2009-11-11 10:26:57 +0100" MODIFIED_BY="Nicole Skoetz" NO="5" P_CHI2="0.1615554792364472" P_Q="0.11744552744685377" P_Z="1.346950006989142E-7" Q="2.4510632067293487" RANDOM="NO" SCALE="11.52" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="547" WEIGHT="100.00000000000001" Z="5.272340338222807">
<NAME>Sensitivity analysis: Progression-free survival (excluding Fisher 2000, fixed-effects model)</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.955028165112204E-4" CI_END="0.9184309807771693" CI_START="0.5823163957298195" DF="1" EFFECT_SIZE="0.7313121210897331" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.036953474953030155" LOG_CI_START="-0.2348409817024799" LOG_EFFECT_SIZE="-0.13589722832775505" MODIFIED="2009-02-02 16:03:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9862848840842228" P_Z="0.007103121097772084" STUDIES="2" TAU2="0.0" TOTAL_1="313" TOTAL_2="313" WEIGHT="51.472068304653206" Z="2.6919705796127213">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<IV_DATA CI_END="1.0143763086622724" CI_START="0.5250436119799194" EFFECT_SIZE="0.7297888742690568" ESTIMABLE="YES" ESTIMATE="-0.315" LOG_CI_END="0.006199097460571484" LOG_CI_START="-0.2798046210596202" LOG_EFFECT_SIZE="-0.13680276179952433" ORDER="36" SE="0.168" STUDY_ID="STD-Aviles-2004" TOTAL_1="191" TOTAL_2="193" WEIGHT="24.64137930602855"/>
<IV_DATA CI_END="1.0045645876475173" CI_START="0.5344301705365678" EFFECT_SIZE="0.7327138758693325" ESTIMABLE="YES" ESTIMATE="-0.311" LOG_CI_END="0.001977864585680521" LOG_CI_START="-0.27210903232950306" LOG_EFFECT_SIZE="-0.13506558387191134" ORDER="37" SE="0.161" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" WEIGHT="26.83068899862466"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.100445830746925" CI_END="0.7121135608673277" CI_START="0.44539703805234365" DF="2" EFFECT_SIZE="0.5631813835410534" ESTIMABLE="YES" I2="51.224815969933545" ID="CMP-001.05.02" LOG_CI_END="-0.1474507438274859" LOG_CI_START="-0.35125267540660576" LOG_EFFECT_SIZE="-0.24935170961704584" MODIFIED="2009-02-02 16:03:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12870648312667254" P_Z="1.618388231935868E-6" STUDIES="3" TAU2="0.0" TOTAL_1="229" TOTAL_2="234" WEIGHT="48.52793169534681" Z="4.796032761280961">
<NAME>Studies evaluating Interferon therapy plus CT vs CT alone</NAME>
<IV_DATA CI_END="0.6464202383542712" CI_START="0.04044976128130064" EFFECT_SIZE="0.1617020232675885" ESTIMABLE="YES" ESTIMATE="-1.822" LOG_CI_END="-0.18948505497482168" LOG_CI_START="-1.3930840370806281" LOG_EFFECT_SIZE="-0.7912845460277248" ORDER="33" SE="0.707" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="1.3913767748527055"/>
<IV_DATA CI_END="0.9033131342983701" CI_START="0.4693934332089478" EFFECT_SIZE="0.6511599291810325" ESTIMABLE="YES" ESTIMATE="-0.429" LOG_CI_END="-0.044161675019614086" LOG_CI_START="-0.328462990453376" LOG_EFFECT_SIZE="-0.18631233273649506" ORDER="34" SE="0.167" STUDY_ID="STD-Smalley-2001" TOTAL_1="78" TOTAL_2="88" WEIGHT="24.937369196936057"/>
<IV_DATA CI_END="0.7319183062471849" CI_START="0.3657103599023065" EFFECT_SIZE="0.5173684443380216" ESTIMABLE="YES" ESTIMATE="-0.659" LOG_CI_END="-0.13553739042521346" LOG_CI_START="-0.4368627367232724" LOG_EFFECT_SIZE="-0.28620006357424294" ORDER="35" SE="0.177" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="123" TOTAL_2="119" WEIGHT="22.199185723558045"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="13.935410057170689" CI_END="25.183108996540014" CI_START="1.279848822099435" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="5.677197582084265" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="14" I2="71.29614425704153" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.4011093451797876" LOG_CI_START="0.10715867308104723" LOG_EFFECT_SIZE="0.7541340091304174" METHOD="MH" MODIFIED="2009-11-11 10:27:18 +0100" MODIFIED_BY="Nicole Skoetz" NO="6" P_CHI2="0.007504105177143727" P_Q="0.0" P_Z="0.02233668803423043" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.7947128329771431" TOTALS="YES" TOTAL_1="416" TOTAL_2="381" WEIGHT="100.0" Z="2.284593268173097">
<NAME>Toxicity (any severity): Leukocytopenia/ Granulocytopenia/ Neutropenia</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="201.6004483824203" CI_START="0.650192669441127" EFFECT_SIZE="11.448979591836734" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3044914936950867" LOG_CI_START="-0.18695793123979143" LOG_EFFECT_SIZE="1.0587667812276478" ORDER="72" O_E="0.0" SE="1.463489725080303" STUDY_ID="STD-Aviles-1996" TOTAL_1="48" TOTAL_2="50" VAR="2.141802175415621" WEIGHT="14.675696894983702"/>
<DICH_DATA CI_END="1287.6356129144472" CI_START="4.9917972669801145" EFFECT_SIZE="80.17241379310344" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="0" LOG_CI_END="3.1097929797240016" LOG_CI_START="0.6982569389300317" LOG_EFFECT_SIZE="1.9040249593270167" ORDER="73" O_E="0.0" SE="1.416548207658302" STUDY_ID="STD-Fisher-2000" TOTAL_1="144" TOTAL_2="124" VAR="2.0066088246199483" WEIGHT="15.19763553033419"/>
<DICH_DATA CI_END="2.934223847312663" CI_START="0.17825460165224086" EFFECT_SIZE="0.7232142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4674932424126387" LOG_CI_START="-0.7489592499957025" LOG_EFFECT_SIZE="-0.14073300379153186" ORDER="71" O_E="0.0" SE="0.7145502155776111" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="0.5105820105820105" WEIGHT="25.06017885180075"/>
<DICH_DATA CI_END="155.92583531152872" CI_START="0.5007255832106438" EFFECT_SIZE="8.836065573770492" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.1929180792918137" LOG_CI_START="-0.3004002189398706" LOG_EFFECT_SIZE="0.9462589301759716" ORDER="69" O_E="0.0" SE="1.464587510505919" STUDY_ID="STD-Rohatiner-2001" TOTAL_1="60" TOTAL_2="48" VAR="2.145016575929925" WEIGHT="14.663723085934695"/>
<DICH_DATA CI_END="8.988370258827393" CI_START="2.5164091268719115" EFFECT_SIZE="4.7558823529411764" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="10" LOG_CI_END="0.9536809540512317" LOG_CI_START="0.40078125167706025" LOG_EFFECT_SIZE="0.677231102864146" ORDER="70" O_E="0.0" SE="0.32477602207225514" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="0.10547946451307796" WEIGHT="30.40276563694666"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005107056249081395" CI_END="3.15011103988628" CI_START="1.0579362317773247" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8255455631721276" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.49832586272926277" LOG_CI_START="0.02445949092992301" LOG_EFFECT_SIZE="0.26139267682959283" METHOD="MH" MODIFIED="2009-09-28 12:40:04 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9430287371514872" P_Q="0.0" P_Z="0.030595188304799008" Q="0.0" RANDOM="NO" SCALE="39.45910215288513" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="159" WEIGHT="100.0" Z="2.162298330912003">
<NAME>Toxicity (any severity): Neurologic symptoms</NAME>
<GROUP_LABEL_1>Interferon Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.005107056249081395" CI_END="3.15011103988628" CI_START="1.0579362317773247" DF="1" EFFECT_SIZE="1.8255455631721276" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.49832586272926277" LOG_CI_START="0.02445949092992301" LOG_EFFECT_SIZE="0.26139267682959283" NO="1" P_CHI2="0.9430287371514872" P_Z="0.030595188304799008" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="159" WEIGHT="100.0" Z="2.162298330912003">
<NAME>Studies evaluating Inteferon therapy plus CT vs CT alone</NAME>
<DICH_DATA CI_END="9.676828845653498" CI_START="0.38436018807676475" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9857330597391738" LOG_CI_START="-0.41526160277767526" LOG_EFFECT_SIZE="0.2852357284807493" ORDER="44" O_E="0.0" SE="0.8229511997978235" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="0.6772486772486772" WEIGHT="11.798000125778252"/>
<DICH_DATA CI_END="3.234609819669851" CI_START="1.0148028765386006" EFFECT_SIZE="1.811764705882353" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.5098219006510225" LOG_CI_START="0.006381689593318096" LOG_EFFECT_SIZE="0.25810179512217035" ORDER="45" O_E="0.0" SE="0.2957232720445319" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="0.08745225362872422" WEIGHT="88.20199987422176"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.741563292709265" CI_END="84.74817049670125" CI_START="0.850745381966068" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="8.491119754198593" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="6" I2="63.52446056382011" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.9281303316330747" LOG_CI_START="-0.07020039967217333" LOG_EFFECT_SIZE="0.9289649659804508" METHOD="MH" MODIFIED="2009-02-02 16:59:07 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.09776915652228968" P_Q="0.0" P_Z="0.06841572703363469" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.9248902461069224" TOTALS="YES" TOTAL_1="184" TOTAL_2="182" WEIGHT="100.0" Z="1.8222587960021115">
<NAME>Toxicity (any severity): Flu-like symptoms</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="589.3403314669148" CI_START="2.251739352410211" DF="0" EFFECT_SIZE="36.42857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="2.770366163026543" LOG_CI_START="0.35251811781285325" LOG_EFFECT_SIZE="1.5614421404196983" MODIFIED="2009-02-02 16:59:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.011358139073635616" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="34.95356160772348" Z="2.5314827912564426">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<DICH_DATA CI_END="589.3403314669148" CI_START="2.251739352410211" EFFECT_SIZE="36.42857142857143" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.770366163026543" LOG_CI_START="0.35251811781285325" LOG_EFFECT_SIZE="1.5614421404196983" ORDER="47" O_E="0.0" SE="1.4202559102993715" STUDY_ID="STD-Aviles-1996" TOTAL_1="48" TOTAL_2="50" VAR="2.017126850740296" WEIGHT="34.95356160772348"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.192521906419477" CI_START="1.6396658624588962" DF="0" EFFECT_SIZE="3.8823529411764706" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.9634346734961092" LOG_CI_START="0.21475535483108016" LOG_EFFECT_SIZE="0.5890950141635947" MODIFIED="2009-02-02 16:59:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.002039782470318774" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="132" WEIGHT="65.04643839227651" Z="3.084378003900351">
<NAME>Studies evaluating Inteferon therapy plus CT vs CT alone</NAME>
<DICH_DATA CI_END="9.192521906419477" CI_START="1.6396658624588962" EFFECT_SIZE="3.8823529411764706" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9634346734961092" LOG_CI_START="0.21475535483108016" LOG_EFFECT_SIZE="0.5890950141635947" ORDER="46" O_E="0.0" SE="0.43977793780623553" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="0.19340463458110516" WEIGHT="65.04643839227651"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.115586294806494" CI_END="15.406450752737575" CI_START="2.166831731343894" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="5.77781847745486" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="4" I2="51.40425065260269" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.1877026000397173" LOG_CI_START="0.3358251868222413" LOG_EFFECT_SIZE="0.7617638934309792" METHOD="MH" MODIFIED="2009-11-08 21:33:07 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.12773583736858263" P_Q="0.0" P_Z="4.5614594014570595E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="209" WEIGHT="100.0" Z="3.505269121313283">
<NAME>Toxicity (any severity): Thrombocytopenia</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.365897479771887" CI_START="0.1460669044278781" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8038596402026922" LOG_CI_START="-0.835448174569156" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="66" O_E="0.0" SE="0.9629375251015391" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="0.9272486772486772" WEIGHT="44.69420148722576"/>
<DICH_DATA CI_END="36.909938190674566" CI_START="2.0673392333417167" EFFECT_SIZE="8.735294117647058" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.5671433179273981" LOG_CI_START="0.31541174662251636" LOG_EFFECT_SIZE="0.9412775322749571" ORDER="64" O_E="0.0" SE="0.7352733211556961" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="0.5406268568033274" WEIGHT="44.55125627991055"/>
<DICH_DATA CI_END="233.8195484088369" CI_START="0.7829861487956897" EFFECT_SIZE="13.53061224489796" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3688808173954787" LOG_CI_START="-0.10624592064295972" LOG_EFFECT_SIZE="1.1313174483762596" ORDER="65" O_E="0.0" SE="1.453901697998731" STUDY_ID="STD-Aviles-1996" TOTAL_1="48" TOTAL_2="50" VAR="2.113830147443593" WEIGHT="10.754542232863699"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.052735947068454" CI_END="1.3322784100484464" CI_START="0.9455096856884468" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.122355621331497" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="210" I2="75.16372058954587" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.12459499008443836" LOG_CI_START="-0.024334017935281317" LOG_EFFECT_SIZE="0.050130486074578574" METHOD="MH" MODIFIED="2009-11-08 21:36:46 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.01783906118611478" P_Q="0.0" P_Z="0.18701083012659572" Q="0.0" RANDOM="YES" SCALE="2.570396227381702" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01641127398451117" TOTALS="YES" TOTAL_1="273" TOTAL_2="266" WEIGHT="99.99999999999999" Z="1.319473600746079">
<NAME>Response to treatment: Overall response</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours interferon</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0891933428710396" CI_START="0.9214583541642166" EFFECT_SIZE="1.0018214936247722" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="108" LOG_CI_END="0.037104978276439514" LOG_CI_START="-0.035524288188135744" LOG_EFFECT_SIZE="7.903450441519058E-4" MODIFIED="2009-02-25 17:41:17 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.042662790641958784" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" VAR="0.0018201137053596057" WEIGHT="41.97725844363612"/>
<DICH_DATA CI_END="1.5592208596876551" CI_START="0.9318024658339796" EFFECT_SIZE="1.2053571428571428" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.19290763626005503" LOG_CI_START="-0.03067614461040604" LOG_EFFECT_SIZE="0.08111574582482449" MODIFIED="2009-02-25 17:41:38 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.1313342196408737" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="0.01724867724867725" WEIGHT="22.736327439751275"/>
<DICH_DATA CI_END="1.4148015050749065" CI_START="1.064209571347345" EFFECT_SIZE="1.2270473924251437" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="82" LOG_CI_END="0.1506955131482123" LOG_CI_START="0.027027160588180662" LOG_EFFECT_SIZE="0.08886133686819647" MODIFIED="2009-02-25 17:41:51 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.07264340246198071" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny-1993" TOTAL_1="123" TOTAL_2="119" VAR="0.005277063921253305" WEIGHT="35.28641411661259"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.608307912171767" CI_END="13.465653766861733" CI_START="0.3390687632314953" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.136769189415023" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="15" I2="88.3833151624834" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="1.1292274435587402" LOG_CI_START="-0.46971221783340855" LOG_EFFECT_SIZE="0.3297576128626658" METHOD="MH" MODIFIED="2009-11-08 21:36:46 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.003346345453762445" P_Q="0.0" P_Z="0.41884478697760696" Q="0.0" RANDOM="YES" SCALE="17.091615791395956" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.563245130209283" TOTALS="YES" TOTAL_1="164" TOTAL_2="159" WEIGHT="100.0" Z="0.8084270600630442">
<NAME>Toxicity WHO grade 3 or 4: Haematological toxicity</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.325383300919921" CI_START="0.2776862810362821" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.36649454937829024" LOG_CI_START="-0.5564455758400036" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="71" O_E="0.0" SE="0.5421395981805276" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="0.29391534391534396" WEIGHT="47.4995967299482"/>
<DICH_DATA CI_END="10.120665384394563" CI_START="2.647636961911871" EFFECT_SIZE="5.176470588235294" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="9" LOG_CI_END="1.005209066186727" LOG_CI_START="0.4228584353570626" LOG_EFFECT_SIZE="0.7140337507718947" ORDER="70" O_E="0.0" SE="0.3420756432314588" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="0.11701574569221629" WEIGHT="52.500403270051805"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="70.85838859627778" CI_START="0.11970530163408598" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9124087591240877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="1.8503912717383095" LOG_CI_START="-0.9218866146776266" LOG_EFFECT_SIZE="0.4642523285303415" METHOD="MH" MODIFIED="2009-11-08 21:36:46 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.5115406956070487" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="132" WEIGHT="100.0" Z="0.6564405740974898">
<NAME>Toxicity WHO grade 3 or 4: Flu-like symptoms</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.85838859627778" CI_START="0.11970530163408592" EFFECT_SIZE="2.9124087591240877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8503912717383095" LOG_CI_START="-0.9218866146776268" LOG_EFFECT_SIZE="0.4642523285303415" ORDER="72" O_E="0.0" SE="1.6284497534775806" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="2.651848599601193" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1771572269960051" CI_END="6.381503081396822" CI_START="0.4061518763775467" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.609925293489861" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.8049229832781328" LOG_CI_START="-0.39131153603167496" LOG_EFFECT_SIZE="0.20680572362322888" METHOD="MH" MODIFIED="2009-11-08 21:36:46 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6738277487144462" P_Q="0.0" P_Z="0.49797496911440176" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="159" WEIGHT="100.0" Z="0.6776794408710718">
<NAME>Toxicity WHO grade 3 or 4: Neurologic symptoms</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.676828845653498" CI_START="0.38436018807676475" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9857330597391738" LOG_CI_START="-0.41526160277767526" LOG_EFFECT_SIZE="0.2852357284807493" ORDER="73" O_E="0.0" SE="0.8229511997978235" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="0.6772486772486772" WEIGHT="66.73781572394165"/>
<DICH_DATA CI_END="15.357292434501689" CI_START="0.06134164121111342" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1863146542107295" LOG_CI_START="-1.212244608539465" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="74" O_E="0.0" SE="1.4089255839993011" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="1.9850713012477719" WEIGHT="33.26218427605834"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6212026165249622" CI_END="15.006165361074121" CI_START="0.33976474806846935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2580004414036634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="1.1762697278669334" LOG_CI_START="-0.4688216828935023" LOG_EFFECT_SIZE="0.3537240224867155" METHOD="MH" MODIFIED="2009-11-08 21:36:46 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.43060094141832195" P_Q="0.0" P_Z="0.3993098346921693" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="159" WEIGHT="99.99999999999997" Z="0.8428544942923633">
<NAME>Toxicity WHO grade 3 or 4: Infection / fever</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.651750998933705" CI_START="0.06346319554865361" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1658895293818077" LOG_CI_START="-1.1974780637482711" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="75" O_E="0.0" SE="1.388253823062871" STUDY_ID="STD-Neri-2001" TOTAL_1="28" TOTAL_2="27" VAR="1.9272486772486772" WEIGHT="66.74023394394172"/>
<DICH_DATA CI_END="100.1612313877502" CI_START="0.2352353040831568" EFFECT_SIZE="4.854014598540146" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0006996551396936" LOG_CI_START="-0.628497498846298" LOG_EFFECT_SIZE="0.6861010781466979" ORDER="76" O_E="0.0" SE="1.5444034229871826" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="136" TOTAL_2="132" VAR="2.3851819329345263" WEIGHT="33.25976605605826"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.338387479365654" CI_END="29.936612640441226" CI_START="1.0574365168401072" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="5.626372490024075" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="16" I2="59.11908428880991" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="1.4762026579044825" LOG_CI_START="0.024254303977470314" LOG_EFFECT_SIZE="0.7502284809409765" METHOD="MH" MODIFIED="2009-11-11 10:27:34 +0100" MODIFIED_BY="Nicole Skoetz" NO="15" P_CHI2="0.06185981735770241" P_Q="0.0" P_Z="0.04282168557465241" Q="0.0" RANDOM="YES" SCALE="689.42" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.646891307450319" TOTALS="YES" TOTAL_1="449" TOTAL_2="411" WEIGHT="100.0" Z="2.0254450495343512">
<NAME>Drop-outs</NAME>
<GROUP_LABEL_1>Interferon therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9645044932385067" CI_START="0.9669581636810118" DF="0" EFFECT_SIZE="1.693089430894309" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.471952112932698" LOG_CI_START="-0.014592315653843464" LOG_EFFECT_SIZE="0.22867989863942725" MODIFIED="2009-09-30 11:32:10 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06541687948559356" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="119" WEIGHT="42.08138545429878" Z="1.842398510753168">
<NAME>Studies evaluating Inteferon therapy plus CT vs CT alone</NAME>
<DICH_DATA CI_END="2.9645044932385067" CI_START="0.9669581636810118" EFFECT_SIZE="1.693089430894309" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" LOG_CI_END="0.471952112932698" LOG_CI_START="-0.014592315653843464" LOG_EFFECT_SIZE="0.22867989863942725" MODIFIED="2009-09-30 11:32:10 +0200" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.2857986057854987" STUDY_ID="STD-Solal_x002d_C_x00e9_ligny--1998" TOTAL_1="123" TOTAL_2="119" VAR="0.08168084306893489" WEIGHT="42.08138545429878">
<FOOTNOTE>
Drops out numbers for Solal-
Cèligny 1998 
were
 extracted in reference to the preliminary data reported also in Solal-Cèligny 1993
</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.434683638568563" CI_END="70.33047857278147" CI_START="2.6057546387730897" DF="2" EFFECT_SIZE="13.537502383680556" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="0" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="1.8471435726360856" LOG_CI_START="0.4159335195716424" LOG_EFFECT_SIZE="1.131538546103864" MODIFIED="2009-01-25 19:34:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8046549972948536" P_Z="0.0019406988728245004" STUDIES="3" TAU2="0.0" TOTAL_1="326" TOTAL_2="292" WEIGHT="57.91861454570122" Z="3.0991604520018408">
<NAME>Studies evaluating Interferon therapy vs no further therapy</NAME>
<DICH_DATA CI_END="169.80214028106369" CI_START="0.5295734842294689" EFFECT_SIZE="9.482758620689655" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2299431600327724" LOG_CI_START="-0.27607376817015955" LOG_EFFECT_SIZE="0.9769346959313066" ORDER="79" O_E="0.0" SE="1.472046748610262" STUDY_ID="STD-Fisher-2000" TOTAL_1="144" TOTAL_2="124" VAR="2.166921630094044" WEIGHT="19.072962450644777"/>
<DICH_DATA CI_END="472.90878730663854" CI_START="1.7209931021962765" EFFECT_SIZE="28.528455284552845" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.674777383889243" LOG_CI_START="0.23577912966277367" LOG_EFFECT_SIZE="1.4552782567760083" MODIFIED="2009-01-25 19:34:39 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.432679647768701" STUDY_ID="STD-Hagenbeek-1998" TOTAL_1="122" TOTAL_2="120" VAR="2.0525709731306487" WEIGHT="19.66250915258517"/>
<DICH_DATA CI_END="155.92583531152872" CI_START="0.5007255832106438" EFFECT_SIZE="8.836065573770492" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.1929180792918137" LOG_CI_START="-0.3004002189398706" LOG_EFFECT_SIZE="0.9462589301759716" ORDER="80" O_E="0.0" SE="1.464587510505919" STUDY_ID="STD-Rohatiner-2001" TOTAL_1="60" TOTAL_2="48" VAR="2.145016575929925" WEIGHT="19.183142942471267"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-11-11 10:27:36 +0100" MODIFIED_BY="Nicole Skoetz">
<FIGURE FILENAME="figura-5.jpg.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-09-30 11:26:12 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The relationship between different B-cell lymphomas and the normal physiological compartments of B-cell differentiation.</P>
<P>ALL, acute lymphoblastic leukaemia (<I>courteously from Dogan, 2005: Modern histological classification of low-grade B-cell lymphomas, Best Practice &amp; Research Clinical Haematology, 2005; 18 (1): pp 11-26).</I>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAAFDCAYAAAAkrzSdAACAAElEQVR42uzdB5icVdUH8ChYsIF+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</FILE>
</FIGURE>
<FIGURE FILENAME="Interferon_Fig3_source.bmp.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-11-11 10:18:59 +0100" MODIFIED_BY="Nicole Skoetz" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Progress for the evaluation and inclusion of trials in this review</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcoAAAHxAQAAAADFWsEfAAAIaUlEQVR42u3d32scxx0AcBuD9STn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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-11-11 10:26:05 +0100" MODIFIED_BY="Nicole Skoetz" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.1 Overall Survival (HR, Random effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzwAAAGACAMAAABfv5f7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-11-11 10:26:18 +0100" MODIFIED_BY="Nicole Skoetz" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.2 Overall Survival (HR, fixed effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAysAAAGACAMAAACazQ1qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-11-11 10:26:33 +0100" MODIFIED_BY="Nicole Skoetz" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.3 Progression-free survival (HR, fixed effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAysAAAFgCAMAAACMiRboAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-11-11 10:27:19 +0100" MODIFIED_BY="Nicole Skoetz" NO="6" REF_ID="CMP-001.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.6 Toxicity (any severity): Leukocytopenia/Granulocytopenia/Neutropenia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuAAAADQCAMAAABx5SS/AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-11-06 13:50:10 +0100" MODIFIED_BY="Nicole Skoetz" NO="7" REF_ID="CMP-001.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.7 Toxicity (any severity): Neurologic symptoms.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtEAAADwCAMAAADxeMiPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-11-08 21:36:47 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.13" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.15 Toxicity WHO grade 3 or 4: Neurologic symptoms.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs8AAACgCAMAAADEkXEjAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-11-06 13:50:10 +0100" MODIFIED_BY="Nicole Skoetz" NO="9" REF_ID="CMP-001.08" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.8 Toxicity (any severity): Flu-like symptoms.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuAAAAFQCAMAAADJIjvTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2009-11-08 21:36:47 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-001.10" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.11 Response to treatment: Not achieving complete or partial remission (CR or PR).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuEAAACwCAMAAACW00DbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2009-11-11 10:27:36 +0100" MODIFIED_BY="Nicole Skoetz" NO="11" REF_ID="CMP-001.15" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon maintenance therapy versus not, outcome: 1.17 DROPS-OUT number.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvIAAAGQCAMAAAD7kXSyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-09-28 11:22:01 +0200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-11-11 10:37:23 +0100" MODIFIED_BY="Nicole Skoetz">
<APPENDIX ID="APP-01" MODIFIED="2009-11-11 10:27:54 +0100" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE MODIFIED="2008-10-21 09:48:45 +0200" MODIFIED_BY="Nicole Skoetz">Clarification of terms</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-11 10:27:54 +0100" MODIFIED_BY="Nicole Skoetz">
<P>CONSORT: Consolidated standards of reporting trials<BR/>A statement that was developed to help authors improve the reporting of a randomised clinical trial by using a checklist and flow diagram; it also enables readers to understand a trial's conduct and to assess the validity of the results.</P>
<P>Fixed-effect model:<BR/>A statistical model that stipulates that the units under analysis (e.g. people in a study in a meta-analysis) are the ones of interest, and thus constitute the entire population of units. Only within-study variation is taken to influence the uncertainty of results (as reflected in the confidence interval) of a meta-analysis using a fixed effect model. Variation between the estimates of effect from each study (heterogeneity) does not affect the confidence interval in a fixed effect model. (see also: random-effects model).</P>
<P>FLIPI: Follicular lymphoma international prognostic index.<BR/>The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help in evaluating and choosing these treatments.</P>
<P>HR: Hazard ratio<BR/>The hazard ratio represents the overall reduction in the risk of death on treatment compared to control over the period of follow-up of patients. This is one of the statistical methods that should improve the efficiency and reliability of meta-analyses of the published literature with survival-type endpoints.</P>
<P>IPD: Individual patient data<BR/>In systematic reviews this term refers to the availability of raw data for each participant in each included study, as opposed to aggregate data (summary data for the comparison groups in each study). Reviews using individual patient data require collaboration of the investigators who conducted the original trials, who must provide the necessary data.</P>
<P>ITT: Intention to treat<BR/>An intention-to-treat analysis is one in which all the participants in a trial are analysed according to the intervention to which they were allocated, whether they received it or not. Intention-to-treat analyses are favoured in assessments of effectiveness as they mirror the noncompliance and treatment changes that are likely to occur when the intervention is used in practice, and because of the risk of attrition bias when participants are excluded from the analysis.</P>
<P>Mantel-Haenszel Method (or test)<BR/>A summary Chi<SUP>2</SUP> test for stratified data and used when collecting for confounding. In meta-analyses, the Mantel-Haenszel test is used to analyse data stratified (grouped) by study.</P>
<P>Meta-analysis<BR/>Meta-analyses are statistical techniques that provide a full and comprehensive summary of related studies which have addressed a similar question.<BR/>Sometimes used as synonym for systematic reviews, where the review includes these techniques.</P>
<P>MIU: Million of International Units<BR/>Symbol for one million international units. It represents a measure of the potency or the biological effect expected with a dose of 1 IU.</P>
<P>NNT: Number needed to treat<BR/>It is the number of patients who need to be treated to prevent one outcome. Statistically, it is the inverse of the risk difference.</P>
<P>QUALY: Quality-adjusted life year<BR/>A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services and is often applied in 'cost-utility' analyses (CUA), in the field of Pharmacoeconomics.</P>
<P>QUOROM: Quality of reporting of meta-analyses<BR/>A statement that was developed to help authors improve the quality of reporting of meta-analyses of clinical randomised controlled trials (RCTs) by using a checklist and a flow diagram. The flow diagram provides information about the numbers of RCTs identified, included and excluded and the reasons for exclusion of trials.</P>
<P>Random-effects model:<BR/>A statistical model sometimes used in meta-analysis in which both within-study sampling error (variance) and between-studies variation are included in the assessment of the uncertainty (confidence interval) of the results of a meta-analysis. If there is significant heterogeneity among the results of the included studies, random effects models will give wider confidence intervals than fixed effect models (see also: fixed-effects model).</P>
<P>Randomised controlled trial (RCT) (Synonym: randomised clinical trial, also typed as 'randomized')<BR/>A clinical experiment in which investigators randomly allocate eligible people into intervention groups to receive or not to receive one or more interventions that are being compared. The results are assessed by comparing outcomes in the treatment and control groups.<BR/>
<BR/>REAL: Revised European-American classification of lymphoid neoplasms<BR/>A list of lymphoid neoplasms as recognized by the International Lymphoma Study Group (see text of the background)</P>
<P>SMD: Standardised mean difference<BR/>The difference between two means divided by an estimate of the within-group standard deviation. When an outcome (such as pain) is measured in a variety of ways across studies (using different scales) it may not be possible directly to compare or combine study results in a systematic review. By expressing the effects as a standardised value the results can be combined since they have no units. Standardised mean differences are sometimes referred to as a d index.</P>
<P>WHO: The World Health Organization<BR/>the United Nations specialized agency for health, that was established on 7 April 1948.</P>
<P>WMD: Weighted mean difference (in meta-analysis)<BR/>A method of meta-analysis used to combine measures on continuous scales (such as weight), where the mean, standard deviation and sample size in each group are known. This method assumes that all of the trials have measured the outcome on the same scale.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-11-11 10:37:23 +0100" MODIFIED_BY="Nicole Skoetz" NO="2">
<TITLE MODIFIED="2009-11-11 10:19:11 +0100" MODIFIED_BY="Nicole Skoetz">Definitions for non-Hodgkin's lymphoma</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-11 10:37:23 +0100" MODIFIED_BY="Nicole Skoetz">
<P>
<I>Follicular lymphoma (FL)</I>
</P>
<P>While the older classification systems grouped the neoplasms according to histological or morphological criteria (Kiel classification) or according to their aggressiveness (Working Formulation), REAL and WHO classification systems provide definitions of neoplasms on the basis of morphological, phenotypic, genotypic, and clinical data. (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). FL is a neoplasm of follicle centre B cells and is composed of a mixture of centrocytes (cleaved follicle centre cells) and centroblasts that are arranged, at least partly, into a follicular structure defined as a lymphoma of follicle centre B cells (<LINK REF="REF-DeVita-2005" TYPE="REFERENCE">DeVita 2005</LINK>). A graphical representation of neoplasm subtypes and cell transformation patterns can be seen in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> (courteously provided by <LINK REF="REF-Dogan-2005" TYPE="REFERENCE">Dogan 2005</LINK>). The proportion of centroblasts and centrocytes varies from tumour to tumour, and often within follicles of the same tumour. This has lead to a variety of grading systems to quantify the number of centroblasts. The most widely used is the WHO classification system, for FL based on Berard's criteria (<LINK REF="REF-Mann-1982" TYPE="REFERENCE">Mann 1982</LINK>). FL are subgrouped according to the counts of centroblasts (CB) in 10 neoplastic follicles with 40 x high-power field magnification (hpf), into Grade 1 (0 to 5 CB/hpf), Grade 2 (6 to 15 CB/hpf), or Grade 3 (&gt; 15 CB/hpf) tumours. WHO classification additionally distinguishes between Grade 3a (centroblasts intermingled with centrocytes) and Grade 3b (presence of solid sheets of centroblasts). Although FLs are commonly regarded as indolent lymphomas (<LINK REF="REF-Ott-2002" TYPE="REFERENCE">Ott 2002</LINK>) the histological grading can provide predictive factors, Grade 1 and 2 being indolent but mainly incurable, while Grade 3 is aggressive but potentially curable.</P>
<SUBSECTION>
<HEADING LEVEL="6">Mantle cell lymphoma</HEADING>
<P>Mantle cell lymphoma is a B-cell lymphoma composed of a monomorphical, uniform, small to medium sized lymphocytes reminescent of centrocytes or mantle zone small B-cells, or both. Unlike other low-grade lymphomas, large transformed cells such as centroblasts are absent. Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation (<LINK REF="REF-Hankin-1999" TYPE="REFERENCE">Hankin 1999</LINK>; <LINK REF="REF-Bentz-2004" TYPE="REFERENCE">Bentz 2004</LINK>) which is associated with cyclin D1 hyper-expression. This abnormality, which is characteristic of mantle cell lymphoma, can be demonstrated in virtually all cases by using cytogenetics or fluorescent in situ hybridisation (FISH) for detecting t(11;14) translocation. The prognosis of mantle cell lymphoma is much poorer than for FL, and this has been associated with pathological features such as high mitotic activity and an over-expression of proteins associated with cell proliferation (<LINK REF="REF-Rosenwald-2003" TYPE="REFERENCE">Rosenwald 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other low-grade lymphoma subcategories</HEADING>
<P>The WHO classification includes entities that were originally classified as low-grade B-cell lymphomas in the Kiel classification, or as low-grade or intermediate-grade in the Working Formulation classification system. A list of the subcategories considered by WHO as low-grade B-cell lymphoma, and the relative proportion of all non-Hodgkin's lymphomas (NHL), are reported below.</P>
<P>Types of low-grade B-cell lymphoma in the WHO*classification: frequency (% of all NHL)</P>
<UL>
<LI>Follicular lymphoma: 22%</LI>
<LI>Extranodal marginal zone lymphoma of MALT**: 8%</LI>
<LI>Small lymphocytic lymphoma: 7%</LI>
<LI>Mantle cell lymphoma: 6%</LI>
<LI>Nodal marginal zone lymphoma: 2%</LI>
<LI>Splenic marginal zone lymphoma: &lt; 1%</LI>
<LI>Lymphoplasmacitic lymphoma: 2%</LI>
<LI>Prolymphocytic leukaemia: &lt; 1%</LI>
<LI>Hairy cell leukaemia: &lt; 1%</LI>
</UL>
<P>
<I>* WHO, World Health Organization; ** MALT, mucosa-associated lymphoid tissue.</I>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-01-05 13:21:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-10-21 09:49:01 +0200" MODIFIED_BY="Nicole Skoetz">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-21 09:37:18 +0200" MODIFIED_BY="Nicole Skoetz">
<P>1.Lymphoma Follicular [MESH]<BR/>2.(Lymphoma* near follicular) or (lymphoma* near nodular)<BR/>3.Lymphoma Non Hodgkin [MESH]<BR/>4.Nonhodgkin*<BR/>5.(Non next Hodgkin*)<BR/>6.bcl-2*<BR/>7.#1 or #2 or #3 or #4 or #5 or #6<BR/>8.Interferon Type I [MESH]<BR/>9.interferon*<BR/>10.IFN<BR/>11.#8 or #9 or #10<BR/>12.#7 and #11</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-01-05 13:21:45 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-10-21 09:49:10 +0200" MODIFIED_BY="Nicole Skoetz">MEDLINE search strategy (PubMed)</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-21 09:37:18 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Specific Medline search in PubMed:<BR/>Search ("Interferon-alpha"[Mesh] AND "Lymphoma, Follicular"[Mesh]) OR ("Lymphoma,<BR/>Follicular/drug therapy"[Mesh] OR ("Lymphoma, Follicular/immunology"[Mesh] OR<BR/>"Lymphoma, Follicular/therapy"[Mesh] OR "Lymphoma, Follicular/drug therapy"[mesh])<BR/>AND ("Antineoplastic Agents"[Mesh] OR "Antineoplastic Combined Chemotherapy<BR/>Protocols"[Mesh]) AND interferon[tw]) OR (lymphoma*[tw] AND follicular[tw] AND interferon<BR/>[tw] AND mainten*[tw])</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-01-05 13:21:41 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-10-21 09:49:26 +0200" MODIFIED_BY="Nicole Skoetz">MEDLINE search strategy through OVID</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-21 09:37:18 +0200" MODIFIED_BY="Nicole Skoetz">
<P>1.exp Lymphoma, Follicular/<BR/>2.brill symmer$.tw.<BR/>3.(lymphoma$ adj5 (follicular or nodular)).tw.<BR/>4.Lymphoma, Non-Hodgkin/<BR/>5.non hodgkin$.tw.<BR/>6.nonhodgkin$.tw.<BR/>7.gene$ bcl-2.tw.<BR/>8.or/1-7<BR/>9.exp Interferon Type I/<BR/>10.interferon$.tw.<BR/>11.IFN.tw.<BR/>12.or/9-11<BR/>13.8 and 12</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2009-01-05 13:21:37 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-10-21 09:49:43 +0200" MODIFIED_BY="Nicole Skoetz">MEDLINE RCT filter</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-21 09:37:18 +0200" MODIFIED_BY="Nicole Skoetz">
<P>14.randomized controlled trial.pt.<BR/>15.controlled clinical trial.pt.<BR/>16.randomized controlled trials/<BR/>17.random allocation/<BR/>18.double blind method/<BR/>19.single blind method/<BR/>20.or/14-19<BR/>21.animal/ not (animal/ and human/)<BR/>22.20 not 21<BR/>23.clinical trial.pt.<BR/>24.exp clinical trials/<BR/>25.(clinic$ adj25 trial$).tw.<BR/>26.cross-over studies/<BR/>27.(crossover or cross over or cross-over).tw.<BR/>28.((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>29.placebos/<BR/>30.placebo$.tw.<BR/>31.random$.tw.<BR/>32.research design/<BR/>33.or/23-32<BR/>34.33 not 21<BR/>35.22 or 34<BR/>36.13 and 35</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-09-28 11:22:01 +0200" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>